{"protocolSection": {"identificationModule": {"nctId": "NCT01402986", "orgStudyIdInfo": {"id": "CD-RI-CAT-354-1049"}, "secondaryIdInfos": [{"id": "2011-001360-21", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "MedImmune LLC", "class": "INDUSTRY"}, "briefTitle": "A Safety and Efficacy Study of Tralokinumab in Adults With Asthma", "officialTitle": "A Phase 2b, Randomized, Double-blind Study to Evaluate the Efficacy of Tralokinumab in Adults With Uncontrolled, Severe Asthma"}, "statusModule": {"statusVerifiedDate": "2017-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2011-08"}, "primaryCompletionDateStruct": {"date": "2013-06", "type": "ACTUAL"}, "completionDateStruct": {"date": "2014-02", "type": "ACTUAL"}, "studyFirstSubmitDate": "2011-07-21", "studyFirstSubmitQcDate": "2011-07-26", "studyFirstPostDateStruct": {"date": "2011-07-27", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2016-05-31", "resultsFirstSubmitQcDate": "2017-01-10", "resultsFirstPostDateStruct": {"date": "2017-03-06", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2017-03-03", "lastUpdatePostDateStruct": {"date": "2017-04-04", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "MedImmune LLC", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to determine whether the addition of tralokinumab to standard asthma medication is effective in the treatment of adults with asthma.", "detailedDescription": "Interleukin-13 (IL-13) is a key mediator in the pathogenesis of established asthmatic disease. Tralokinumab is a human monoclonal antibody that blocks IL-13, which may result in improved control of asthma. This study will determine whether the addition of tralokinumab to standard asthma medications results in a reduced rate of asthma exacerbations in subjects with severe asthma."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Asthma", "Tralokinumab", "CAT-354"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 689, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Placebo, Q2W - Cohort 1", "type": "PLACEBO_COMPARATOR", "description": "Participants received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.", "interventionNames": ["Other: Placebo Q2W"]}, {"label": "Tralokinumab 300 mg, Q2W - Cohort 1", "type": "EXPERIMENTAL", "description": "Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.", "interventionNames": ["Biological: Tralokinumab 300 mg, Q2W"]}, {"label": "Placebo, Q2/4W - Cohort 2", "type": "PLACEBO_COMPARATOR", "description": "Participants received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.", "interventionNames": ["Other: Placebo, Q2/4W"]}, {"label": "Tralokinumab 300 mg, Q2/4W - Cohort 2", "type": "EXPERIMENTAL", "description": "Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.", "interventionNames": ["Biological: Tralokinumab 300 mg, Q2/4W"]}], "interventions": [{"type": "OTHER", "name": "Placebo Q2W", "description": "Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.", "armGroupLabels": ["Placebo, Q2W - Cohort 1"]}, {"type": "BIOLOGICAL", "name": "Tralokinumab 300 mg, Q2W", "description": "Participants received tralokinumab 300 mg subcutaneous injection Q2W for a total of 26 doses up to 50 weeks.", "armGroupLabels": ["Tralokinumab 300 mg, Q2W - Cohort 1"], "otherNames": ["CAT-354"]}, {"type": "OTHER", "name": "Placebo, Q2/4W", "description": "Participants received matching placebo subcutaneous injection Q2W for 12 weeks followed by Q4W for 38 weeks (Q2/4W) for a total of 16 doses.", "armGroupLabels": ["Placebo, Q2/4W - Cohort 2"]}, {"type": "BIOLOGICAL", "name": "Tralokinumab 300 mg, Q2/4W", "description": "Participants received tralokinumab 300 mg subcutaneous injection Q2W for 12 weeks followed by Q4W for 38 weeks (Q2/4W) for a total of 16 doses.", "armGroupLabels": ["Tralokinumab 300 mg, Q2/4W - Cohort 2"], "otherNames": ["CAT-354"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Annual Asthma Exacerbation Rate (AER)", "description": "Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed or administered by the investigator or healthcare provider; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. An asthma exacerbation event was considered resolved 7 days after the last dose of oral corticosteroids (OCS) is administered (10 days after administration of an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "timeFrame": "Week 1 up to Week 53"}], "secondaryOutcomes": [{"measure": "Mean Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 53", "description": "Pre- and post-bronchodilator FEV1 at clinic visits (morning) were measured. FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "timeFrame": "Baseline and Week 53"}, {"measure": "Mean Change From Baseline in Forced Expiratory Volume in 6 Second (FEV6) at Week 53", "description": "Pre- and post-bronchodilator FEV6 at clinic visits (morning) were measured. FEV6 was the maximal volume of air exhaled in the six second of a forced expiration from a position of full inspiration. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "timeFrame": "Baseline and Week 53"}, {"measure": "Mean Change From Baseline in Forced Vital Capacity (FVC) at Week 53", "description": "Pre- and post-bronchodilator FVC at clinic visits (morning) were measured. FVC was the volume of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "timeFrame": "Baseline and Week 53"}, {"measure": "Mean Change From Baseline in Ratio of Forced Expiratory Volume in 1 Second (FEV1)/Forced Vital Capacity (FVC) at Week 53", "description": "Pre- and post-bronchodilator FEV1 and FVC at clinic visits (morning) were measured. FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. FVC was the volume of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Ratio of FEV1/FVC was analysed. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "timeFrame": "Baseline and Week 53"}, {"measure": "Mean Change From Baseline in Inspiratory Capacity (IC) at Week 53", "description": "Pre- and post-bronchodilator IC at clinic visits (morning) were measured. IC was measured by spirometry. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "timeFrame": "Baseline and Week 53"}, {"measure": "Mean Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 53 at Home", "description": "Pre- and post-bronchodilator FEV1 at home (morning and evening) were measured. FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "timeFrame": "Day 1 - Day 7 (Baseline) and Day 365 - Day 371 (Week 53)"}, {"measure": "Mean Change From Baseline in Peak Expiratory Flow (PEF) at Week 53 at Home", "description": "The PEF is a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for PEF was performed at home (morning and evening) while sitting or standing prior to using any medication (if needed) for asthma. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "timeFrame": "Day 1 - Day 7 (Baseline) and Day 365 - Day 371 (Week 53)"}, {"measure": "Change From Baseline in Mean Asthma Control Questionnaire (6-items) (ACQ-6) Score at Week 53", "description": "Asthma Control Questionnaire (ACQ) is a participant-reported questionnaire to assess the asthma control with 6 items assessing night-time waking, symptoms on waking, activity limitation, shortness of breath, wheeze, and rescue short-acting beta agonist use. Each item was rated on a 7-point Likert scale ranging from 0 (no impairment) to 6 (maximum impairment). Overall ACQ score was the mean of the 6 item scores with a score range of 0 (well controlled) to 6 (extremely poor controlled). Data collected on Day 1 prior to dosing was considered as baseline. Results were reported for overall ACQ score. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "timeFrame": "Baseline and Week 53"}, {"measure": "Change From Baseline in Asthma Quality of Life Questionnaire Standardized Version (AQLQ[S]) Score at Week 53", "description": "AQLQ: a 32-item questionnaire evaluating quality of life of participants with asthma including 4 domains (symptoms, activity limitations, emotional function, and environmental stimuli). Participants were asked to recall their experiences during the previous 2 weeks and to score each of the 32 questions on a 7-point scale ranging from 7 (no impairment) to 1 (severe impairment). The overall score was calculated as the mean response to all questions. The 4 domain scores were the means of the responses to the questions in each of the domains. Overall AQLQ score and 4 domain scores ranged from 7 (no impairment) to 1 (severe impairment). Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "timeFrame": "Baseline and Week 53"}, {"measure": "Number of Participants With European Quality of Life 5 Dimensions (EQ-5D) Scores at Week 53", "description": "The utility-based EQ-5D questionnaire comprises of two parts and provides a generic measure of health for clinical and economic appraisal. The health state valuation was the summary score of mobility, self-care, usual activities, pain/discomfort and anxiety/depression on a 3 category scale (no problem, moderate problem, severe problems) that reflects increasing levels of difficulty. The minimum possible value is 5 (one point for each dimension) and the maximum possible values is 15 (3 points for each dimension). Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "timeFrame": "Week 53"}, {"measure": "Change From Baseline in European Quality of Life 5 Dimensions (EQ-5D) Visual Analog Scale (VAS) at Week 53", "description": "The utility-based EQ-5D questionnaire comprises of two parts and provides a generic measure of health for clinical and economic appraisal. The EQ-5D VAS was measured from 0 (worst imaginable health state) to 100 (best imaginable health state). Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "timeFrame": "Baseline and Week 53"}, {"measure": "Change From Baseline in Assessing Symptoms of Moderate-to-severe Asthma (ASMA) at Week 53", "description": "There were 3 symptom questions in the ASMA diary: daytime frequency (question 1), daytime severity (question 2) and nighttime severity (question 6). All symptom questions were scored from 0 to 4 averaged, where a higher score indicated greater frequency or severity. Daily Asthma symptom scores were averaged weekly for participants with at least 4 non-missing records each week. The baseline score was calculated from Day -7 to Day -1. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "timeFrame": "Day -7 - Day -1 (Baseline) and Day 365 - Day 371 (Week 53)"}, {"measure": "Change From Baseline in Rescue Medication Use at Week 53", "description": "Rescue medication use was collected from 3 questions: daytime use in response to symptoms (question 3), daytime prophylactic use (question 4) and nighttime use (question 7). Rescue medication use questions were first assessed using a dichotomous response option (YES/NO). If the participants reported YES, there was a subsequent question about the number of times rescue medication was used (questions 3a, 4a, and 7a). Daily average scores were summarized each week for all participants with at least 4 non-missing records each week. Days with no reported rescue medication use were represented as 0 and included in the calculation with participants who reported yes and completed questions 3a, 4a and 7a. The baseline scores were calculated from Day -7 to Day -1. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "timeFrame": "Day -7 - Day -1 (Baseline) and Day 365 - Day 371 (Week 53)"}, {"measure": "Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (TESAEs)", "description": "An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between administration of study drug and up to Week 75 that were absent before treatment or that worsened relative to pre-treatment state. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "timeFrame": "Baseline and Week 75"}, {"measure": "Observed Serum Tralokinumab Concentration at Week 53", "description": "Tralokinumab concentrations that were below limit of quantification (LOQ) of the pharmacokinetic (PK) assay (LOQ = 0.500 microgram per milliliter \\[mcg/mL\\]) were replaced by LOQ/2 = 0.250 mcg/mL; results were reported to 3 significant figures level of precision. Observed serum tralokinumab concentration at Week 53 was reported.", "timeFrame": "Week 53"}, {"measure": "Percentage of Participants With Anti-Drug Antibodies (ADA) to Tralokinumab", "description": "Immunogenicity assessment included determination of anti-drug (tralokinumab) antibodies in serum samples. ADA positive was defined as a titer greater than or equal to (\\>=13) at any point in the study. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "timeFrame": "Baseline and Week 75"}, {"measure": "Severe Annual Asthma Exacerbation Rate (AER)", "description": "Severe annualized AER was assessed based on AER data up to Week 53. Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed or administered by the investigator; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. An asthma exacerbation event was considered resolved 7 days after the last dose of oral corticosteroids is administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "timeFrame": "Week 1 up to Week 53"}, {"measure": "Time to First Exacerbation Through Week 53", "description": "Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "timeFrame": "Week 1 up to Week 53"}, {"measure": "Time to First Severe Exacerbation Through Week 53", "description": "Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "timeFrame": "Week 1 up to Week 53"}, {"measure": "Annual Asthma Exacerbation Rate (AER) by Baseline Serum Periostin", "description": "Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. AER was evaluated by subgroup baseline serum periostin greater than or equal to (\\>=) or less than (\\<) median, \\>= or \\< 25th percentile and \\>= or \\< 75th percentile. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "timeFrame": "Week 1 up to Week 53"}, {"measure": "Annual Asthma Exacerbation Rate (AER) by T-helper-2 (Th2) Status", "description": "Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. AER was evaluated by subgroup Th2 status. Th2-high included those participants who had immunoglobulin E (IgE) \\>100 international unit per milliliter (IU/mL) and blood eosinophils \\>= 0.14 \\* 10 power 9 per Liter. Th2 low would include those participants who do not meet Th2 high status. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "timeFrame": "Week 1 up to Week 53"}, {"measure": "Annual Asthma Exacerbation Rate (AER) by Baseline Peripheral Blood Eosinophil Count", "description": "Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. AER evaluated by subgroups baseline peripheral blood eosinophil counts. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "timeFrame": "Week 1 up to Week 53"}, {"measure": "Annual Asthma Exacerbation Rate (AER) by Baseline FEV1 Reversibility", "description": "Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. AER evaluated by subgroup baseline FEV1 reversibility \\>=12% and \\<12%. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "timeFrame": "Week 1 up to Week 53"}, {"measure": "Annual Asthma Exacerbation Rate (AER) by Baseline FEV1% Predicted", "description": "Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. AER was evaluated by subgroup baseline FEV1% predicaed. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "timeFrame": "Week 1 up to Week 53"}, {"measure": "Annual Asthma Exacerbation Rate (AER) by Asthma Exacerbations in the Past Year", "description": "Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. AER evaluated by subgroup as asthma exacerbations in the past year. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "timeFrame": "Week 1 up to Week 53"}, {"measure": "Severe Asthma Exacerbation Rate (AER) by Baseline Serum Periostin", "description": "Severe AER was assessed based on AER data up to Week 53. Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. Severe AER evaluated by subgroup baseline serum periostin. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "timeFrame": "Week 1 up to Week 53"}, {"measure": "Severe Asthma Exacerbation Rate (AER) by Baseline FEV1 Reversibility", "description": "Severe AER was assessed based on AER data up to Week 53. Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. Severe AER was evaluated by subgroup FEV1 reversibility. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "timeFrame": "Week 1 up to Week 53"}, {"measure": "Severe Asthma Exacerbation Rate (AER) by T-helper-2 (Th2) Status", "description": "Severe AER was assessed based on AER data up to Week 53. An asthma exacerbation is a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 days. It was considered resolved 7 days after last dose of OCS administered (10 days after injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. Severe AER was evaluated by subgroup Th2 status. Th2-high include participants who had IgE \\>100 IU/mL and blood eosinophils \\>=0.14\\*10\\^9/Liter. Th2 low would include participants who do not meet Th2 high status. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "timeFrame": "Week 1 up to Week 53"}, {"measure": "Severe Asthma Exacerbation Rate (AER) by Baseline Peripheral Blood Eosinophil Count", "description": "Severe AER was assessed based on AER data up to Week 53. Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. Severe AER was evaluated by subgroup baseline peripheral blood eosinophil count. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "timeFrame": "Week 1 up to Week 53"}, {"measure": "Percent Change From Baseline in Prebronchodilator FEV1 at Week 53 in Subgroups", "description": "Prebronchodilator FEV1 was evaluated by subgroups. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "timeFrame": "Week 1 up to Week 53"}, {"measure": "Change From Baseline in Mean ACQ-6 Scores at Week 53 in Subgroups", "description": "Asthma Control Questionnaire (ACQ) is a participant-reported questionnaire to assess the asthma control with 6 items assessing night-time waking, symptoms on waking, activity limitation, shortness of breath, wheeze, and rescue short-acting beta agonist use. Each item was rated on a 7-point Likert scale ranging from 0 (no impairment) to 6 (maximum impairment). Overall ACQ score was the mean of the 6 item scores with a score range of 0 (well controlled) to 6 (extremely poor controlled). Data collected on Day 1 prior to dosing was considered as baseline. Results were reported for overall ACQ score. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "timeFrame": "Week 1 up to Week 53"}, {"measure": "Change From Baseline in Total AQLQ(S) Scores at Week 53 in Subgroups", "description": "AQLQ: a 32-item questionnaire evaluating quality of life of participants with asthma including 4 domains (symptoms, activity limitations, emotional function, and environmental stimuli). Participants were asked to recall their experiences during the previous 2 weeks and to score each of the 32 questions on a 7-point scale ranging from 7 (no impairment) to 1 (severe impairment). The overall score was calculated as the mean response to all questions. The 4 domain scores were the means of the responses to the questions in each of the domains. Overall AQLQ score and 4 domain scores ranged from 7 (no impairment) to 1 (severe impairment). Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "timeFrame": "Week 1 up to Week 53"}, {"measure": "Annual Asthma Exacerbation Rate (AER) by Atopic Asthma Status", "description": "Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. AER was evaluated by subgroup Atopic and Non-atopic asthma status. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "timeFrame": "Week 1 up to Week 53"}, {"measure": "Annual Asthma Exacerbation Rate (AER) by Chronic OCS Use", "description": "Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. AER evaluated by subgroup chronic OCS use. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "timeFrame": "Week 1 up to Week 53"}, {"measure": "Change From Baseline in Percentage of Nighttime Awakening at Week 53", "description": "Scores for nighttime awakenings were generated based on the single item (question 5) that had a dichotomous response option (YES/NO). Nighttime awakenings were averaged weekly for participants with at least 4 non-missing records each week. The baseline score was calculated with data from Day -7 to Day -1. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "timeFrame": "Day -7 - Day -1 (Baseline) and Day 365 - Day 371 (Week 53)"}, {"measure": "Change From Baseline in Overall Activity Limitations at Week 53", "description": "There were 3 activity limitation questions in the ASMA diary. All activity questions were scored from 0 to 4 and averaged, where the higher score indicated greater limitation. Activity limitation scores were averaged weekly for participants with at least 4 non-missing records each week. The baseline score was calculated from Day -7 to Day -1. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "timeFrame": "Day -7 - Day -1 (Baseline) and Day 365 - Day 371 (Week 53)"}, {"measure": "Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 53", "description": "Pre- and post-bronchodilator FEV1 at clinic visits (morning) were measured. FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms. Baseline for FEV1 was measured in liters.", "timeFrame": "Baseline and Week 53"}, {"measure": "Percent Change From Baseline in Forced Expiratory Volume in 6 Second (FEV6) at Week 53", "description": "Pre- and post-bronchodilator FEV6 at clinic visits (morning) were measured. FEV6 was the maximal volume of air exhaled in the six second of a forced expiration from a position of full inspiration. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms. Baseline for FEV6 was measured in liters.", "timeFrame": "Baseline and Week 53"}, {"measure": "Percent Change From Baseline in Forced Vital Capacity (FVC) at Week 53", "description": "Pre- and post-bronchodilator FVC at clinic visits (morning) were measured. FVC was the volume of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms. Baseline for FVC was measured in liters.", "timeFrame": "Baseline and Week 53"}, {"measure": "Percent Change From Baseline in Inspiratory Capacity (IC) at Week 53", "description": "Pre- and post-bronchodilator IC at clinic visits (morning) were measured. IC was measured by spirometry. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms. Baseline for IC was measured in liters.", "timeFrame": "Baseline and Week 53"}, {"measure": "Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 53 at Home", "description": "Pre- and post-bronchodilator FEV1 at home (morning and evening) were measured. FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "timeFrame": "Day 1 - Day 7 (Baseline) and Day 365 - Day 371 (Week 53)"}, {"measure": "Percent Change From Baseline in Peak Expiratory Flow (PEF) at Week 53 at Home", "description": "The PEF is a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for PEF was performed at home (morning and evening) while sitting or standing prior to using any medication (if needed) for asthma. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "timeFrame": "Day 1 - Day 7 (Baseline) and Day 365 - Day 371 (Week 53)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Age 18-75 years\n* Body mass index (BMI) between 16-40 kilogram per square meter (kg/m\\^2) at Visit 1\n* Uncontrolled severe asthma\n* A chest x-ray with no abnormality\n* Females of childbearing potential who are sexually active with a non-sterilized male partner must use highly effective contraception from Day 1\n* Non-sterilized males or sterilized males who are less than or equal to (=\\<) 1 year post-vasectomy who are sexually active with a female partner of childbearing potential must use a highly effective method of contraception\n\nExclusion Criteria:\n\n* Employee of the clinical study site or any other individuals directly involved with the conduct of the study, or immediate family members of such individuals\n* Pregnant or breastfeeding women\n* Any other respiratory disease\n* Previously taken tralokinumab (the study drug)\n* Current smoker or a history of smoking which would be more than 1 pack per day for 10 years\n* Known immune deficiency\n* History of cancer\n* Hepatitis B, C or Human Immuno-deficiency Virus (HIV)\n* Any disease which may cause complications whilst taking the study drug.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Edward Piper, MBBS", "affiliation": "Sponsor GmbH", "role": "STUDY_DIRECTOR"}, {"name": "Christopher Brightling", "affiliation": "Institute for Lung Health", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Research Site", "city": "Rancho Mirage", "state": "California", "country": "United States", "geoPoint": {"lat": 33.73974, "lon": -116.41279}}, {"facility": "Research Site", "city": "Centennial", "state": "Colorado", "country": "United States", "geoPoint": {"lat": 39.57916, "lon": -104.87692}}, {"facility": "Research Site", "city": "New Haven", "state": "Connecticut", "country": "United States", "geoPoint": {"lat": 41.30815, "lon": -72.92816}}, {"facility": "Research Site", "city": "Cocoa", "state": "Florida", "country": "United States", "geoPoint": {"lat": 28.38612, "lon": -80.742}}, {"facility": "Research Site", "city": "Miami", "state": "Florida", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Research Site", "city": "Winter Park", "state": "Florida", "country": "United States", "geoPoint": {"lat": 28.6, "lon": -81.33924}}, {"facility": "Research Site", "city": "Albany", "state": "Georgia", "country": "United States", "geoPoint": {"lat": 31.57851, "lon": -84.15574}}, {"facility": "Research Site", "city": "Fargo", "state": "North Dakota", "country": "United States", "geoPoint": {"lat": 46.87719, "lon": -96.7898}}, {"facility": "Research Site", "city": "Philadelphia", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "Research Site", "city": "Upland", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 39.85261, "lon": -75.38269}}, {"facility": "Research Site", "city": "Killeen", "state": "Texas", "country": "United States", "geoPoint": {"lat": 31.11712, "lon": -97.7278}}, {"facility": "Research Site", "city": "Buenos Aires", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Research Site", "city": "Ciudad de Buenos Aires", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Research Site", "city": "Monte Grande", "country": "Argentina"}, {"facility": "Research Site", "city": "Ranelagh", "country": "Argentina", "geoPoint": {"lat": -34.79591, "lon": -58.1977}}, {"facility": "Research Site", "city": "Rosario", "country": "Argentina", "geoPoint": {"lat": -32.94682, "lon": -60.63932}}, {"facility": "Research Site", "city": "Calgary", "state": "Alberta", "country": "Canada", "geoPoint": {"lat": 51.05011, "lon": -114.08529}}, {"facility": "Research Site", "city": "Ottawa", "state": "Ontario", "country": "Canada", "geoPoint": {"lat": 45.41117, "lon": -75.69812}}, {"facility": "Research Site", "city": "Montreal", "state": "Quebec", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "Research Site", "city": "Quebec", "country": "Canada", "geoPoint": {"lat": 46.81228, "lon": -71.21454}}, {"facility": "Research Site", "city": "Quillota", "country": "Chile", "geoPoint": {"lat": -32.88341, "lon": -71.24882}}, {"facility": "Research Site", "city": "Santiago", "country": "Chile", "geoPoint": {"lat": -33.45694, "lon": -70.64827}}, {"facility": "Research Site", "city": "Valparaiso", "country": "Chile", "geoPoint": {"lat": -33.03932, "lon": -71.62725}}, {"facility": "Research Site", "city": "Vi\u00f1a del Mar", "country": "Chile", "geoPoint": {"lat": -33.02457, "lon": -71.55183}}, {"facility": "Research Site", "city": "Jindrichuv Hradec", "country": "Czech Republic", "geoPoint": {"lat": 49.14404, "lon": 15.00301}}, {"facility": "Research Site", "city": "Plzen", "country": "Czech Republic", "geoPoint": {"lat": 49.74747, "lon": 13.37759}}, {"facility": "Research Site", "city": "Rokycany", "country": "Czech Republic", "geoPoint": {"lat": 49.7427, "lon": 13.59459}}, {"facility": "Research Site", "city": "Marseille Cedex 20", "country": "France", "geoPoint": {"lat": 43.29551, "lon": 5.38958}}, {"facility": "Research Site", "city": "Montpellier", "country": "France", "geoPoint": {"lat": 43.61092, "lon": 3.87723}}, {"facility": "Research Site", "city": "Nantes Cedex 1", "country": "France", "geoPoint": {"lat": 47.21725, "lon": -1.55336}}, {"facility": "Research Site", "city": "Paris Cedex 18", "country": "France", "geoPoint": {"lat": 48.85341, "lon": 2.3488}}, {"facility": "Research Site", "city": "Perpignan", "country": "France", "geoPoint": {"lat": 42.69764, "lon": 2.89541}}, {"facility": "Research Site", "city": "Pessac", "country": "France", "geoPoint": {"lat": 44.81011, "lon": -0.64129}}, {"facility": "Research Site", "city": "Strasbourg Cedex", "country": "France", "geoPoint": {"lat": 48.58392, "lon": 7.74553}}, {"facility": "Research Site", "city": "Berlin", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Research Site", "city": "Frankfurt", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "Research Site", "city": "L\u00fcbeck", "country": "Germany", "geoPoint": {"lat": 53.86893, "lon": 10.68729}}, {"facility": "Research Site", "city": "Mainz", "country": "Germany", "geoPoint": {"lat": 49.98419, "lon": 8.2791}}, {"facility": "Research Site", "city": "Chuo-ku", "country": "Japan", "geoPoint": {"lat": 35.57779, "lon": 139.71685}}, {"facility": "Research Site", "city": "Fujisawa-shi", "country": "Japan", "geoPoint": {"lat": 35.34926, "lon": 139.47666}}, {"facility": "Research Site", "city": "Fukuoka-shi", "country": "Japan", "geoPoint": {"lat": 33.6, "lon": 130.41667}}, {"facility": "Research Site", "city": "Habikino-shi", "country": "Japan", "geoPoint": {"lat": 34.55276, "lon": 135.59097}}, {"facility": "Research Site", "city": "Hiroshima-shi", "country": "Japan", "geoPoint": {"lat": 34.4, "lon": 132.45}}, {"facility": "Research Site", "city": "Itabashi-ku", "country": "Japan", "geoPoint": {"lat": 35.74893, "lon": 139.71497}}, {"facility": "Research Site", "city": "Kagoshima-shi", "country": "Japan", "geoPoint": {"lat": 31.56667, "lon": 130.55}}, {"facility": "Research Site", "city": "Kahoku-gun", "country": "Japan"}, {"facility": "Research Site", "city": "Kishiwada-shi", "country": "Japan", "geoPoint": {"lat": 34.46667, "lon": 135.36667}}, {"facility": "Research Site", "city": "Kobe-shi", "country": "Japan", "geoPoint": {"lat": 34.6913, "lon": 135.183}}, {"facility": "Research Site", "city": "Kyoto-shi", "country": "Japan", "geoPoint": {"lat": 35.02107, "lon": 135.75385}}, {"facility": "Research Site", "city": "Maebashi-shi", "country": "Japan", "geoPoint": {"lat": 36.4, "lon": 139.08333}}, {"facility": "Research Site", "city": "Morioka-shi", "country": "Japan", "geoPoint": {"lat": 39.7, "lon": 141.15}}, {"facility": "Research Site", "city": "Naka-gun", "country": "Japan", "geoPoint": {"lat": 36.05, "lon": 140.16667}}, {"facility": "Research Site", "city": "Sagamihara-shi", "country": "Japan", "geoPoint": {"lat": 35.54899, "lon": 139.26064}}, {"facility": "Research Site", "city": "Sakaide-shi", "country": "Japan"}, {"facility": "Research Site", "city": "Sapporo-shi", "country": "Japan", "geoPoint": {"lat": 43.06667, "lon": 141.35}}, {"facility": "Research Site", "city": "Sumida-ku", "country": "Japan"}, {"facility": "Research Site", "city": "Takatsuki-shi", "country": "Japan", "geoPoint": {"lat": 34.84833, "lon": 135.61678}}, {"facility": "Research Site", "city": "Tomakomai-shi", "country": "Japan", "geoPoint": {"lat": 42.63694, "lon": 141.60333}}, {"facility": "Research Site", "city": "Wakayama-shi", "country": "Japan", "geoPoint": {"lat": 34.23333, "lon": 135.16667}}, {"facility": "Research Site", "city": "Yokohama-shi", "country": "Japan", "geoPoint": {"lat": 35.43333, "lon": 139.65}}, {"facility": "Research Site", "city": "Bucheon-si", "country": "Korea, Republic of", "geoPoint": {"lat": 37.49889, "lon": 126.78306}}, {"facility": "Research Site", "city": "Incheon", "country": "Korea, Republic of", "geoPoint": {"lat": 37.45646, "lon": 126.70515}}, {"facility": "Research Site", "city": "Seoul", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Research Site", "city": "Suwon-si", "country": "Korea, Republic of", "geoPoint": {"lat": 37.29111, "lon": 127.00889}}, {"facility": "Research Site", "city": "Culiacan", "country": "Mexico", "geoPoint": {"lat": 24.79032, "lon": -107.38782}}, {"facility": "Research Site", "city": "Guadalajara", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "Research Site", "city": "Morelia", "country": "Mexico", "geoPoint": {"lat": 19.70078, "lon": -101.18443}}, {"facility": "Research Site", "city": "M\u00e9xico", "country": "Mexico", "geoPoint": {"lat": 19.42847, "lon": -99.12766}}, {"facility": "Research Site", "city": "Santiago de Quer\u00e9taro", "country": "Mexico", "geoPoint": {"lat": 20.58806, "lon": -100.38806}}, {"facility": "Research Site", "city": "Tampico", "country": "Mexico", "geoPoint": {"lat": 22.26695, "lon": -97.86815}}, {"facility": "Research Site", "city": "Villahermosa", "country": "Mexico", "geoPoint": {"lat": 17.98689, "lon": -92.93028}}, {"facility": "Research Site", "city": "Iloilo City", "country": "Philippines", "geoPoint": {"lat": 10.69694, "lon": 122.56444}}, {"facility": "Research Site", "city": "Lipa City", "country": "Philippines", "geoPoint": {"lat": 13.9411, "lon": 121.1631}}, {"facility": "Research Site", "city": "Quezon City", "country": "Philippines", "geoPoint": {"lat": 14.6488, "lon": 121.0509}}, {"facility": "Research Site", "city": "Wroc\u0142aw", "country": "Poland", "geoPoint": {"lat": 51.1, "lon": 17.03333}}, {"facility": "Research Site", "city": "Zabrze", "country": "Poland", "geoPoint": {"lat": 50.32492, "lon": 18.78576}}, {"facility": "Research Site", "city": "\u0141\u00f3d\u017a", "country": "Poland", "geoPoint": {"lat": 51.75, "lon": 19.46667}}, {"facility": "Research Site", "city": "Ekaterinburg", "country": "Russian Federation", "geoPoint": {"lat": 56.8519, "lon": 60.6122}}, {"facility": "Research Site", "city": "Moscow", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Research Site", "city": "Novosibirsk", "country": "Russian Federation", "geoPoint": {"lat": 55.0415, "lon": 82.9346}}, {"facility": "Research Site", "city": "Saint Petersburg", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Research Site", "city": "Vladikavkaz", "country": "Russian Federation", "geoPoint": {"lat": 43.03667, "lon": 44.66778}}, {"facility": "Research Site", "city": "Yekaterinburg", "country": "Russian Federation", "geoPoint": {"lat": 56.8519, "lon": 60.6122}}, {"facility": "Research Site", "city": "Barcelona", "country": "Spain", "geoPoint": {"lat": 41.38879, "lon": 2.15899}}, {"facility": "Research Site", "city": "Madrid", "country": "Spain", "geoPoint": {"lat": 40.4165, "lon": -3.70256}}, {"facility": "Research Site", "city": "Pamplona", "country": "Spain", "geoPoint": {"lat": 42.81687, "lon": -1.64323}}, {"facility": "Research Site", "city": "Sagunto(Valencia)", "country": "Spain"}, {"facility": "Research Site", "city": "Santander", "country": "Spain", "geoPoint": {"lat": 43.46472, "lon": -3.80444}}, {"facility": "Research Site", "city": "Leicester", "country": "United Kingdom", "geoPoint": {"lat": 52.6386, "lon": -1.13169}}, {"facility": "Research Site", "city": "Manchester", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}]}, "referencesModule": {"references": [{"pmid": "26231288", "type": "BACKGROUND", "citation": "Brightling CE, Chanez P, Leigh R, O'Byrne PM, Korn S, She D, May RD, Streicher K, Ranade K, Piper E. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med. 2015 Sep;3(9):692-701. doi: 10.1016/S2213-2600(15)00197-6. Epub 2015 Jul 28."}, {"pmid": "28758192", "type": "DERIVED", "citation": "Baverel PG, White N, Vicini P, Karlsson MO, Agoram B. Dose-Exposure-Response Relationship of the Investigational Anti-Interleukin-13 Monoclonal Antibody Tralokinumab in Patients With Severe, Uncontrolled Asthma. Clin Pharmacol Ther. 2018 May;103(5):826-835. doi: 10.1002/cpt.803. Epub 2017 Sep 28."}], "seeAlsoLinks": [{"label": "CD-RI-CAT-354-1049 Redacted Protocol", "url": "http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=51&filename=CAT-354_CP1049_Protocol_Legal%20IP_Redacted_02Sep14.pdf"}, {"label": "CD-RI-CAT-354-1049 SAP", "url": "http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=51&filename=CAT-354_CP1049_SAP_08Aug14.pdf"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "A total of 689 participants were screened, out of which 452 participants were randomized into this study", "groups": [{"id": "FG000", "title": "Placebo, Q2W - Cohort 1", "description": "Participants received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks."}, {"id": "FG001", "title": "Tralokinumab 300 mg, Q2W - Cohort 1", "description": "Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks."}, {"id": "FG002", "title": "Placebo, Q2/4W - Cohort 2", "description": "Participants received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}, {"id": "FG003", "title": "Tralokinumab 300 mg, Q2/4W - Cohort 2", "description": "Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "76"}, {"groupId": "FG001", "numSubjects": "150"}, {"groupId": "FG002", "numSubjects": "75"}, {"groupId": "FG003", "numSubjects": "151"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "67"}, {"groupId": "FG001", "numSubjects": "135"}, {"groupId": "FG002", "numSubjects": "67"}, {"groupId": "FG003", "numSubjects": "129"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "15"}, {"groupId": "FG002", "numSubjects": "8"}, {"groupId": "FG003", "numSubjects": "22"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "10"}, {"groupId": "FG002", "numSubjects": "7"}, {"groupId": "FG003", "numSubjects": "13"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "2"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}]}, {"type": "Other", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "6"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "The intention-to-treat (ITT) population included all participants who were randomized into the study.", "groups": [{"id": "BG000", "title": "Placebo, Q2W - Cohort 1", "description": "Participants received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks."}, {"id": "BG001", "title": "Tralokinumab 300 mg, Q2W - Cohort 1", "description": "Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks."}, {"id": "BG002", "title": "Placebo, Q2/4W - Cohort 2", "description": "Participants received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}, {"id": "BG003", "title": "Tralokinumab 300 mg, Q2/4W - Cohort 2", "description": "Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "76"}, {"groupId": "BG001", "value": "150"}, {"groupId": "BG002", "value": "75"}, {"groupId": "BG003", "value": "151"}, {"groupId": "BG004", "value": "452"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "48.8", "spread": "12.1"}, {"groupId": "BG001", "value": "49.7", "spread": "12.2"}, {"groupId": "BG002", "value": "51.7", "spread": "13.6"}, {"groupId": "BG003", "value": "50.5", "spread": "11.8"}, {"groupId": "BG004", "value": "50.1", "spread": "12.0"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "51"}, {"groupId": "BG001", "value": "100"}, {"groupId": "BG002", "value": "46"}, {"groupId": "BG003", "value": "100"}, {"groupId": "BG004", "value": "297"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "25"}, {"groupId": "BG001", "value": "50"}, {"groupId": "BG002", "value": "29"}, {"groupId": "BG003", "value": "51"}, {"groupId": "BG004", "value": "155"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Annual Asthma Exacerbation Rate (AER)", "description": "Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed or administered by the investigator or healthcare provider; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. An asthma exacerbation event was considered resolved 7 days after the last dose of oral corticosteroids (OCS) is administered (10 days after administration of an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "populationDescription": "The intent-to-treat (ITT) population included all participants who were randomized into the study.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "AER events/person-year", "timeFrame": "Week 1 up to Week 53", "groups": [{"id": "OG000", "title": "Placebo Total", "description": "Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}, {"id": "OG001", "title": "Tralokinumab 300 mg, Q2W - Cohort 1", "description": "Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks."}, {"id": "OG002", "title": "Tralokinumab 300 mg, Q2/4W - Cohort 2", "description": "Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "151"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.90", "lowerLimit": "0.75", "upperLimit": "1.08"}, {"groupId": "OG001", "value": "0.91", "lowerLimit": "0.76", "upperLimit": "1.08"}, {"groupId": "OG002", "value": "0.97", "lowerLimit": "0.81", "upperLimit": "1.14"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The 95 percent (%) confidence interval (CI) for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 versus \\[vs\\] more than \\[\\>\\] 2 but less than or equal to \\[=\\<\\] 6), atopic asthma status (atopic/non-atopic), chronic oral corticosteroid (OCS) use (presence vs absence) and geographical region as the covariates.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.709", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "0.94", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.67", "ciUpperLimit": "1.31"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\> 2 but =\\< 6), atopic asthma status (atopic/non-atopic), chronic OCS use (presence vs absence) and geographical region as the covariates.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.904", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "1.02", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.71", "ciUpperLimit": "1.46"}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 53", "description": "Pre- and post-bronchodilator FEV1 at clinic visits (morning) were measured. FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "populationDescription": "The ITT population included all participants who were randomized into the study. Here \"n\" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "liters", "timeFrame": "Baseline and Week 53", "groups": [{"id": "OG000", "title": "Placebo Total", "description": "Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}, {"id": "OG001", "title": "Tralokinumab 300 mg, Q2W - Cohort 1", "description": "Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks."}, {"id": "OG002", "title": "Tralokinumab 300 mg, Q2/4W - Cohort 2", "description": "Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "151"}]}], "classes": [{"title": "Pre-bronchodilator: Baseline (n=147,146,146)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.926", "spread": "0.050"}, {"groupId": "OG001", "value": "1.922", "spread": "0.056"}, {"groupId": "OG002", "value": "1.934", "spread": "0.059"}]}]}, {"title": "Post-bronchodilator: Baseline (n=147,141,146)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.153", "spread": "0.053"}, {"groupId": "OG001", "value": "2.094", "spread": "0.061"}, {"groupId": "OG002", "value": "2.110", "spread": "0.061"}]}]}, {"title": "Pre-bronchodilator: Week 53 (n=125,130,122)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.018", "spread": "0.035"}, {"groupId": "OG001", "value": "0.128", "spread": "0.032"}, {"groupId": "OG002", "value": "0.032", "spread": "0.026"}]}]}, {"title": "Post-bronchodilator: Week 53 (n=125,126,120)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.058", "spread": "0.027"}, {"groupId": "OG001", "value": "0.085", "spread": "0.029"}, {"groupId": "OG002", "value": "-0.009", "spread": "0.025"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in Forced Expiratory Volume in 6 Second (FEV6) at Week 53", "description": "Pre- and post-bronchodilator FEV6 at clinic visits (morning) were measured. FEV6 was the maximal volume of air exhaled in the six second of a forced expiration from a position of full inspiration. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "populationDescription": "The ITT population included all participants who were randomized into the study. Here \"n\" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "liters", "timeFrame": "Baseline and Week 53", "groups": [{"id": "OG000", "title": "Placebo Total", "description": "Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}, {"id": "OG001", "title": "Tralokinumab 300 mg, Q2W - Cohort 1", "description": "Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks."}, {"id": "OG002", "title": "Tralokinumab 300 mg, Q2/4W - Cohort 2", "description": "Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "151"}]}], "classes": [{"title": "Pre-bronchodilator: Baseline (n=147,146,146)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.830", "spread": "0.064"}, {"groupId": "OG001", "value": "2.809", "spread": "0.072"}, {"groupId": "OG002", "value": "2.827", "spread": "0.074"}]}]}, {"title": "Post-bronchodilator: Baseline (n=147,141,146)", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.055", "spread": "0.067"}, {"groupId": "OG001", "value": "2.981", "spread": "0.075"}, {"groupId": "OG002", "value": "2.980", "spread": "0.076"}]}]}, {"title": "Pre-bronchodilator: Week 53 (n=125,130,122)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.007", "spread": "0.036"}, {"groupId": "OG001", "value": "0.117", "spread": "0.037"}, {"groupId": "OG002", "value": "0.003", "spread": "0.031"}]}]}, {"title": "Post-bronchodilator: Week 53 (n=125,126,120)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.057", "spread": "0.030"}, {"groupId": "OG001", "value": "0.060", "spread": "0.033"}, {"groupId": "OG002", "value": "-0.024", "spread": "0.029"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in Forced Vital Capacity (FVC) at Week 53", "description": "Pre- and post-bronchodilator FVC at clinic visits (morning) were measured. FVC was the volume of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "populationDescription": "The ITT population included all participants who were randomized into the study. Here \"n\" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "liters", "timeFrame": "Baseline and Week 53", "groups": [{"id": "OG000", "title": "Placebo Total", "description": "Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}, {"id": "OG001", "title": "Tralokinumab 300 mg, Q2W - Cohort 1", "description": "Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks."}, {"id": "OG002", "title": "Tralokinumab 300 mg, Q2/4W - Cohort 2", "description": "Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "151"}]}], "classes": [{"title": "Pre-bronchodilator: Baseline (n=147,146,146)", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.003", "spread": "0.069"}, {"groupId": "OG001", "value": "2.955", "spread": "0.075"}, {"groupId": "OG002", "value": "2.993", "spread": "0.079"}]}]}, {"title": "Post-bronchodilator: Baseline (n=147,141,146)", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.225", "spread": "0.072"}, {"groupId": "OG001", "value": "3.133", "spread": "0.078"}, {"groupId": "OG002", "value": "3.125", "spread": "0.080"}]}]}, {"title": "Pre-bronchodilator: Week 53 (n=125,130,122)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.001", "spread": "0.039"}, {"groupId": "OG001", "value": "0.110", "spread": "0.042"}, {"groupId": "OG002", "value": "-0.018", "spread": "0.032"}]}]}, {"title": "Post-bronchodilator: Week 53 (n=125,126,120)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.071", "spread": "0.032"}, {"groupId": "OG001", "value": "0.045", "spread": "0.034"}, {"groupId": "OG002", "value": "-0.030", "spread": "0.031"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in Ratio of Forced Expiratory Volume in 1 Second (FEV1)/Forced Vital Capacity (FVC) at Week 53", "description": "Pre- and post-bronchodilator FEV1 and FVC at clinic visits (morning) were measured. FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. FVC was the volume of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Ratio of FEV1/FVC was analysed. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "populationDescription": "The ITT population included all participants who were randomized into the study. Here \"n\" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage of ratio", "timeFrame": "Baseline and Week 53", "groups": [{"id": "OG000", "title": "Placebo Total", "description": "Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}, {"id": "OG001", "title": "Tralokinumab 300 mg, Q2W - Cohort 1", "description": "Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks."}, {"id": "OG002", "title": "Tralokinumab 300 mg, Q2/4W - Cohort 2", "description": "Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "151"}]}], "classes": [{"title": "Pre-bronchodilator: Baseline (n=147,146,146)", "categories": [{"measurements": [{"groupId": "OG000", "value": "64.508", "spread": "0.986"}, {"groupId": "OG001", "value": "65.071", "spread": "1.013"}, {"groupId": "OG002", "value": "65.008", "spread": "1.009"}]}]}, {"title": "Post-bronchodilator: Baseline (n=147,141,146)", "categories": [{"measurements": [{"groupId": "OG000", "value": "67.152", "spread": "0.997"}, {"groupId": "OG001", "value": "66.831", "spread": "1.056"}, {"groupId": "OG002", "value": "67.883", "spread": "1.010"}]}]}, {"title": "Pre-bronchodilator: Week 53 (n=125,130,122)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.320", "spread": "0.685"}, {"groupId": "OG001", "value": "1.695", "spread": "0.517"}, {"groupId": "OG002", "value": "1.155", "spread": "0.527"}]}]}, {"title": "Post-bronchodilator: Week 53 (n=125,126,120)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.512", "spread": "0.513"}, {"groupId": "OG001", "value": "1.593", "spread": "0.563"}, {"groupId": "OG002", "value": "0.032", "spread": "0.484"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in Inspiratory Capacity (IC) at Week 53", "description": "Pre- and post-bronchodilator IC at clinic visits (morning) were measured. IC was measured by spirometry. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "populationDescription": "The ITT population included all participants who were randomized into the study. Here \"n\" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "liters", "timeFrame": "Baseline and Week 53", "groups": [{"id": "OG000", "title": "Placebo Total", "description": "Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}, {"id": "OG001", "title": "Tralokinumab 300 mg, Q2W - Cohort 1", "description": "Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks."}, {"id": "OG002", "title": "Tralokinumab 300 mg, Q2/4W - Cohort 2", "description": "Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "151"}]}], "classes": [{"title": "Pre-bronchodilator: Baseline (n=140,138,143)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.022", "spread": "0.001"}, {"groupId": "OG001", "value": "0.023", "spread": "0.001"}, {"groupId": "OG002", "value": "0.023", "spread": "0.001"}]}]}, {"title": "Post-bronchodilator: Baseline (n=140,133,135)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.024", "spread": "0.001"}, {"groupId": "OG001", "value": "0.024", "spread": "0.001"}, {"groupId": "OG002", "value": "0.024", "spread": "0.001"}]}]}, {"title": "Pre-bronchodilator: Week 53 (n=108,109,103)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.001", "spread": "0.001"}, {"groupId": "OG001", "value": "0.000", "spread": "0.000"}, {"groupId": "OG002", "value": "0.001", "spread": "0.001"}]}]}, {"title": "Post-bronchodilator: Week 53 (n=108,109,104)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.000", "spread": "0.001"}, {"groupId": "OG001", "value": "0.001", "spread": "0.001"}, {"groupId": "OG002", "value": "0.000", "spread": "0.001"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 53 at Home", "description": "Pre- and post-bronchodilator FEV1 at home (morning and evening) were measured. FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "populationDescription": "The ITT population included all participants who were randomized into the study. Here \"n\" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "liters", "timeFrame": "Day 1 - Day 7 (Baseline) and Day 365 - Day 371 (Week 53)", "groups": [{"id": "OG000", "title": "Placebo Total", "description": "Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}, {"id": "OG001", "title": "Tralokinumab 300 mg, Q2W - Cohort 1", "description": "Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks."}, {"id": "OG002", "title": "Tralokinumab 300 mg, Q2/4W - Cohort 2", "description": "Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "151"}]}], "classes": [{"title": "Day 1-7: Morning (n=151,149,149)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.63", "spread": "0.05"}, {"groupId": "OG001", "value": "1.61", "spread": "0.05"}, {"groupId": "OG002", "value": "1.66", "spread": "0.05"}]}]}, {"title": "Change at Day 365-371: Morning (n=124,119,114)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.12", "spread": "0.06"}, {"groupId": "OG001", "value": "0.01", "spread": "0.04"}, {"groupId": "OG002", "value": "-0.07", "spread": "0.06"}]}]}, {"title": "Day 1-7: Evening (n=149,147,148)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.61", "spread": "0.05"}, {"groupId": "OG001", "value": "1.68", "spread": "0.05"}, {"groupId": "OG002", "value": "1.65", "spread": "0.05"}]}]}, {"title": "Change at Day 365-371: Evening (n=120,116,112)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.08", "spread": "0.05"}, {"groupId": "OG001", "value": "-0.08", "spread": "0.05"}, {"groupId": "OG002", "value": "-0.12", "spread": "0.05"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in Peak Expiratory Flow (PEF) at Week 53 at Home", "description": "The PEF is a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for PEF was performed at home (morning and evening) while sitting or standing prior to using any medication (if needed) for asthma. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "populationDescription": "The ITT population included all participants who were randomized into the study. Here \"n\" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "liters per minute", "timeFrame": "Day 1 - Day 7 (Baseline) and Day 365 - Day 371 (Week 53)", "groups": [{"id": "OG000", "title": "Placebo Total", "description": "Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}, {"id": "OG001", "title": "Tralokinumab 300 mg, Q2W - Cohort 1", "description": "Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks."}, {"id": "OG002", "title": "Tralokinumab 300 mg, Q2/4W - Cohort 2", "description": "Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "151"}]}], "classes": [{"title": "Day 1-7: Morning (n=151,149,149)", "categories": [{"measurements": [{"groupId": "OG000", "value": "273.7", "spread": "8.7"}, {"groupId": "OG001", "value": "271.0", "spread": "9.7"}, {"groupId": "OG002", "value": "281.2", "spread": "9.9"}]}]}, {"title": "Change at Day 365-371: Morning (n=124,119,114)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-23.1", "spread": "8.8"}, {"groupId": "OG001", "value": "-8.0", "spread": "7.9"}, {"groupId": "OG002", "value": "-24.0", "spread": "9.6"}]}]}, {"title": "Day 1-7: Evening (n=149,147,148)", "categories": [{"measurements": [{"groupId": "OG000", "value": "276.0", "spread": "8.9"}, {"groupId": "OG001", "value": "287.6", "spread": "9.9"}, {"groupId": "OG002", "value": "283.8", "spread": "10.0"}]}]}, {"title": "Change at Day 365-371: Evening (n=120,116,112)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-16.4", "spread": "8.7"}, {"groupId": "OG001", "value": "-27.0", "spread": "8.2"}, {"groupId": "OG002", "value": "-36.5", "spread": "8.8"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean Asthma Control Questionnaire (6-items) (ACQ-6) Score at Week 53", "description": "Asthma Control Questionnaire (ACQ) is a participant-reported questionnaire to assess the asthma control with 6 items assessing night-time waking, symptoms on waking, activity limitation, shortness of breath, wheeze, and rescue short-acting beta agonist use. Each item was rated on a 7-point Likert scale ranging from 0 (no impairment) to 6 (maximum impairment). Overall ACQ score was the mean of the 6 item scores with a score range of 0 (well controlled) to 6 (extremely poor controlled). Data collected on Day 1 prior to dosing was considered as baseline. Results were reported for overall ACQ score. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "populationDescription": "The ITT population included all participants who were randomized into the study. Here \"n\" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and Week 53", "groups": [{"id": "OG000", "title": "Placebo Total", "description": "Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}, {"id": "OG001", "title": "Tralokinumab 300 mg, Q2W - Cohort 1", "description": "Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks."}, {"id": "OG002", "title": "Tralokinumab 300 mg, Q2/4W - Cohort 2", "description": "Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "151"}]}], "classes": [{"title": "Baseline (n=149,147,148)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.52", "spread": "0.07"}, {"groupId": "OG001", "value": "2.59", "spread": "0.09"}, {"groupId": "OG002", "value": "2.54", "spread": "0.08"}]}]}, {"title": "Change at Week 53 (n=118,115,112)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.82", "spread": "0.10"}, {"groupId": "OG001", "value": "-1.02", "spread": "0.10"}, {"groupId": "OG002", "value": "-0.93", "spread": "0.11"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Asthma Quality of Life Questionnaire Standardized Version (AQLQ[S]) Score at Week 53", "description": "AQLQ: a 32-item questionnaire evaluating quality of life of participants with asthma including 4 domains (symptoms, activity limitations, emotional function, and environmental stimuli). Participants were asked to recall their experiences during the previous 2 weeks and to score each of the 32 questions on a 7-point scale ranging from 7 (no impairment) to 1 (severe impairment). The overall score was calculated as the mean response to all questions. The 4 domain scores were the means of the responses to the questions in each of the domains. Overall AQLQ score and 4 domain scores ranged from 7 (no impairment) to 1 (severe impairment). Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "populationDescription": "The ITT population included all participants who were randomized into the study. Here \"n\" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and Week 53", "groups": [{"id": "OG000", "title": "Placebo Total", "description": "Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}, {"id": "OG001", "title": "Tralokinumab 300 mg, Q2W - Cohort 1", "description": "Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks."}, {"id": "OG002", "title": "Tralokinumab 300 mg, Q2/4W - Cohort 2", "description": "Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "151"}]}], "classes": [{"title": "Baseline: Overall (n=147,142,141)", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.05", "spread": "0.09"}, {"groupId": "OG001", "value": "3.98", "spread": "0.09"}, {"groupId": "OG002", "value": "4.08", "spread": "0.09"}]}]}, {"title": "Week 53: Overall (n=107,109,101)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.85", "spread": "0.10"}, {"groupId": "OG001", "value": "1.04", "spread": "0.10"}, {"groupId": "OG002", "value": "1.00", "spread": "0.12"}]}]}, {"title": "Baseline: Symptoms (n=147,142,141)", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.10", "spread": "0.09"}, {"groupId": "OG001", "value": "4.03", "spread": "0.09"}, {"groupId": "OG002", "value": "4.13", "spread": "0.09"}]}]}, {"title": "Week 53: Symptoms (n=107,109,101)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.85", "spread": "0.11"}, {"groupId": "OG001", "value": "1.14", "spread": "0.12"}, {"groupId": "OG002", "value": "1.05", "spread": "0.13"}]}]}, {"title": "Baseline: Activity limitation (n=147,142,141)", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.04", "spread": "0.08"}, {"groupId": "OG001", "value": "4.04", "spread": "0.09"}, {"groupId": "OG002", "value": "4.13", "spread": "0.09"}]}]}, {"title": "Week 53: Activity limitation (n=107,109,101)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.81", "spread": "0.10"}, {"groupId": "OG001", "value": "0.96", "spread": "0.10"}, {"groupId": "OG002", "value": "0.93", "spread": "0.12"}]}]}, {"title": "Baseline: Emotional Function (n=147,142,141)", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.14", "spread": "0.12"}, {"groupId": "OG001", "value": "3.91", "spread": "0.12"}, {"groupId": "OG002", "value": "4.02", "spread": "0.11"}]}]}, {"title": "Week 53: Emotional Function (n=107,109,101)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.89", "spread": "0.12"}, {"groupId": "OG001", "value": "1.10", "spread": "0.12"}, {"groupId": "OG002", "value": "1.09", "spread": "0.15"}]}]}, {"title": "Baseline: Environmental stimuli (n=147,142,141)", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.80", "spread": "0.11"}, {"groupId": "OG001", "value": "3.76", "spread": "0.12"}, {"groupId": "OG002", "value": "3.89", "spread": "0.12"}]}]}, {"title": "Week 53: Environmental stimuli (n=107,109,101)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.88", "spread": "0.13"}, {"groupId": "OG001", "value": "0.86", "spread": "0.14"}, {"groupId": "OG002", "value": "0.97", "spread": "0.14"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With European Quality of Life 5 Dimensions (EQ-5D) Scores at Week 53", "description": "The utility-based EQ-5D questionnaire comprises of two parts and provides a generic measure of health for clinical and economic appraisal. The health state valuation was the summary score of mobility, self-care, usual activities, pain/discomfort and anxiety/depression on a 3 category scale (no problem, moderate problem, severe problems) that reflects increasing levels of difficulty. The minimum possible value is 5 (one point for each dimension) and the maximum possible values is 15 (3 points for each dimension). Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "populationDescription": "The ITT population included all participants who were randomized into the study.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Week 53", "groups": [{"id": "OG000", "title": "Placebo Total", "description": "Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}, {"id": "OG001", "title": "Tralokinumab 300 mg, Q2W - Cohort 1", "description": "Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks."}, {"id": "OG002", "title": "Tralokinumab 300 mg, Q2/4W - Cohort 2", "description": "Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "151"}]}], "classes": [{"title": "Mobility - No problem", "categories": [{"measurements": [{"groupId": "OG000", "value": "107", "spread": "0.10"}, {"groupId": "OG001", "value": "118", "spread": "0.10"}, {"groupId": "OG002", "value": "106", "spread": "0.12"}]}]}, {"title": "Mobility - Moderate problem", "categories": [{"measurements": [{"groupId": "OG000", "value": "26", "spread": "0.12"}, {"groupId": "OG001", "value": "18", "spread": "0.12"}, {"groupId": "OG002", "value": "23", "spread": "0.11"}]}]}, {"title": "Mobility - Severe Problem", "categories": [{"measurements": [{"groupId": "OG000", "value": "1", "spread": "0.12"}, {"groupId": "OG001", "value": "0", "spread": "0.12"}, {"groupId": "OG002", "value": "1", "spread": "0.15"}]}]}, {"title": "Mobility - Missing", "categories": [{"measurements": [{"groupId": "OG000", "value": "17", "spread": "0.13"}, {"groupId": "OG001", "value": "14", "spread": "0.14"}, {"groupId": "OG002", "value": "21", "spread": "0.14"}]}]}, {"title": "Self-care - No Problem", "categories": [{"measurements": [{"groupId": "OG000", "value": "122"}, {"groupId": "OG001", "value": "127"}, {"groupId": "OG002", "value": "122"}]}]}, {"title": "Self-care - Moderate Problem", "categories": [{"measurements": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "9"}, {"groupId": "OG002", "value": "7"}]}]}, {"title": "Self-care - Severe Problem", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "Self-care - Missing", "categories": [{"measurements": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "14"}, {"groupId": "OG002", "value": "21"}]}]}, {"title": "Usual activities - No Problem", "categories": [{"measurements": [{"groupId": "OG000", "value": "89"}, {"groupId": "OG001", "value": "106"}, {"groupId": "OG002", "value": "100"}]}]}, {"title": "Usual activities - Moderate Problem", "categories": [{"measurements": [{"groupId": "OG000", "value": "43"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "30"}]}]}, {"title": "Usual activities - Severe Problem", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Usual activities - Missing", "categories": [{"measurements": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "14"}, {"groupId": "OG002", "value": "21"}]}]}, {"title": "Pain/discomfort - No problem", "categories": [{"measurements": [{"groupId": "OG000", "value": "84"}, {"groupId": "OG001", "value": "100"}, {"groupId": "OG002", "value": "77"}]}]}, {"title": "Pain/discomfort - Moderate problem", "categories": [{"measurements": [{"groupId": "OG000", "value": "46"}, {"groupId": "OG001", "value": "34"}, {"groupId": "OG002", "value": "51"}]}]}, {"title": "Pain/discomfort - Severe problem", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "2"}]}]}, {"title": "Pain/discomfort - Missing", "categories": [{"measurements": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "14"}, {"groupId": "OG002", "value": "21"}]}]}, {"title": "Anxiety/depression - No problem", "categories": [{"measurements": [{"groupId": "OG000", "value": "102"}, {"groupId": "OG001", "value": "101"}, {"groupId": "OG002", "value": "101"}]}]}, {"title": "Anxiety/depression - Moderate problem", "categories": [{"measurements": [{"groupId": "OG000", "value": "29"}, {"groupId": "OG001", "value": "34"}, {"groupId": "OG002", "value": "29"}]}]}, {"title": "Anxiety/depression - Severe problem", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Anxiety/depression - Missing", "categories": [{"measurements": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "14"}, {"groupId": "OG002", "value": "21"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in European Quality of Life 5 Dimensions (EQ-5D) Visual Analog Scale (VAS) at Week 53", "description": "The utility-based EQ-5D questionnaire comprises of two parts and provides a generic measure of health for clinical and economic appraisal. The EQ-5D VAS was measured from 0 (worst imaginable health state) to 100 (best imaginable health state). Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "populationDescription": "The ITT population included all participants who were randomized into the study. Here \"n\" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and Week 53", "groups": [{"id": "OG000", "title": "Placebo Total", "description": "Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}, {"id": "OG001", "title": "Tralokinumab 300 mg, Q2W - Cohort 1", "description": "Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks."}, {"id": "OG002", "title": "Tralokinumab 300 mg, Q2/4W - Cohort 2", "description": "Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "130"}, {"groupId": "OG001", "value": "136"}, {"groupId": "OG002", "value": "127"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "8.4", "spread": "1.6"}, {"groupId": "OG001", "value": "9.3", "spread": "1.9"}, {"groupId": "OG002", "value": "7.3", "spread": "1.8"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Assessing Symptoms of Moderate-to-severe Asthma (ASMA) at Week 53", "description": "There were 3 symptom questions in the ASMA diary: daytime frequency (question 1), daytime severity (question 2) and nighttime severity (question 6). All symptom questions were scored from 0 to 4 averaged, where a higher score indicated greater frequency or severity. Daily Asthma symptom scores were averaged weekly for participants with at least 4 non-missing records each week. The baseline score was calculated from Day -7 to Day -1. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "populationDescription": "The ITT population included all participants who were randomized into the study. Here \"n\" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Day -7 - Day -1 (Baseline) and Day 365 - Day 371 (Week 53)", "groups": [{"id": "OG000", "title": "Placebo Total", "description": "Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}, {"id": "OG001", "title": "Tralokinumab 300 mg, Q2W - Cohort 1", "description": "Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks."}, {"id": "OG002", "title": "Tralokinumab 300 mg, Q2/4W - Cohort 2", "description": "Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "151"}]}], "classes": [{"title": "Day -7 - Day -1 (Baseline) (n=151,147,145)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.60", "spread": "0.71"}, {"groupId": "OG001", "value": "1.49", "spread": "0.77"}, {"groupId": "OG002", "value": "1.56", "spread": "0.69"}]}]}, {"title": "Change at Day 365 - Day 371 (n=113,108,108)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.43", "spread": "0.75"}, {"groupId": "OG001", "value": "-0.42", "spread": "0.73"}, {"groupId": "OG002", "value": "-0.49", "spread": "0.78"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Rescue Medication Use at Week 53", "description": "Rescue medication use was collected from 3 questions: daytime use in response to symptoms (question 3), daytime prophylactic use (question 4) and nighttime use (question 7). Rescue medication use questions were first assessed using a dichotomous response option (YES/NO). If the participants reported YES, there was a subsequent question about the number of times rescue medication was used (questions 3a, 4a, and 7a). Daily average scores were summarized each week for all participants with at least 4 non-missing records each week. Days with no reported rescue medication use were represented as 0 and included in the calculation with participants who reported yes and completed questions 3a, 4a and 7a. The baseline scores were calculated from Day -7 to Day -1. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "populationDescription": "The ITT population included all participants who were randomized into the study. Here \"n\" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "use per day", "timeFrame": "Day -7 - Day -1 (Baseline) and Day 365 - Day 371 (Week 53)", "groups": [{"id": "OG000", "title": "Placebo Total", "description": "Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}, {"id": "OG001", "title": "Tralokinumab 300 mg, Q2W - Cohort 1", "description": "Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks."}, {"id": "OG002", "title": "Tralokinumab 300 mg, Q2/4W - Cohort 2", "description": "Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "151"}]}], "classes": [{"title": "Day -7 - Day -1 (Baseline) (n=151,147,145)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.56", "spread": "2.73"}, {"groupId": "OG001", "value": "2.77", "spread": "3.78"}, {"groupId": "OG002", "value": "2.38", "spread": "2.58"}]}]}, {"title": "Change at Day 365 - Day 371 (n=113,108,108)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.86", "spread": "2.20"}, {"groupId": "OG001", "value": "-0.77", "spread": "2.59"}, {"groupId": "OG002", "value": "-1.02", "spread": "2.30"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (TESAEs)", "description": "An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between administration of study drug and up to Week 75 that were absent before treatment or that worsened relative to pre-treatment state. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "populationDescription": "The safety population included all participants who received any investigational product and had safety data available for analysis.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline and Week 75", "groups": [{"id": "OG000", "title": "Placebo Total", "description": "Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}, {"id": "OG001", "title": "Tralokinumab 300 mg, Q2W - Cohort 1", "description": "Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks."}, {"id": "OG002", "title": "Tralokinumab 300 mg, Q2/4W - Cohort 2", "description": "Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "151"}]}], "classes": [{"title": "TEAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "129", "spread": "17.12"}, {"groupId": "OG001", "value": "134", "spread": "19.83"}, {"groupId": "OG002", "value": "128", "spread": "16.98"}]}]}, {"title": "TESAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "21", "spread": "1.6"}, {"groupId": "OG001", "value": "18", "spread": "1.9"}, {"groupId": "OG002", "value": "25", "spread": "1.8"}]}]}]}, {"type": "SECONDARY", "title": "Observed Serum Tralokinumab Concentration at Week 53", "description": "Tralokinumab concentrations that were below limit of quantification (LOQ) of the pharmacokinetic (PK) assay (LOQ = 0.500 microgram per milliliter \\[mcg/mL\\]) were replaced by LOQ/2 = 0.250 mcg/mL; results were reported to 3 significant figures level of precision. Observed serum tralokinumab concentration at Week 53 was reported.", "populationDescription": "The PK population included all participants who received at least one dose of tralokinumab and had at least one quantifiable PK observation. Here \"N\" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "microgram per milliliter", "timeFrame": "Week 53", "groups": [{"id": "OG000", "title": "Tralokinumab 300 mg, Q2W - Cohort 1", "description": "Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks."}, {"id": "OG001", "title": "Tralokinumab 300 mg, Q2/4W - Cohort 2", "description": "Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "136"}, {"groupId": "OG001", "value": "128"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "71.3", "spread": "34.2"}, {"groupId": "OG001", "value": "25.8", "spread": "11.8"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With Anti-Drug Antibodies (ADA) to Tralokinumab", "description": "Immunogenicity assessment included determination of anti-drug (tralokinumab) antibodies in serum samples. ADA positive was defined as a titer greater than or equal to (\\>=13) at any point in the study. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "populationDescription": "The PK population included all participants who received at least one dose of tralokinumab and had at least one quantifiable PK observation. Here \"n\" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline and Week 75", "groups": [{"id": "OG000", "title": "Placebo Total", "description": "Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}, {"id": "OG001", "title": "Tralokinumab 300 mg, Q2W - Cohort 1", "description": "Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks."}, {"id": "OG002", "title": "Tralokinumab 300 mg, Q2/4W - Cohort 2", "description": "Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "151"}]}], "classes": [{"title": "Baseline (Week 1) (n=151,150,151)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.3", "spread": "17.12"}, {"groupId": "OG001", "value": "0.67", "spread": "19.83"}, {"groupId": "OG002", "value": "1.3", "spread": "16.98"}]}]}, {"title": "Week 75 (n=151,150,150)", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.3"}, {"groupId": "OG001", "value": "0.0"}, {"groupId": "OG002", "value": "4.0"}]}]}]}, {"type": "SECONDARY", "title": "Severe Annual Asthma Exacerbation Rate (AER)", "description": "Severe annualized AER was assessed based on AER data up to Week 53. Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed or administered by the investigator; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. An asthma exacerbation event was considered resolved 7 days after the last dose of oral corticosteroids is administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "populationDescription": "The ITT population included all participants who were randomized into the study.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "AER events/person-year", "timeFrame": "Week 1 up to Week 53", "groups": [{"id": "OG000", "title": "Placebo Total", "description": "Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}, {"id": "OG001", "title": "Tralokinumab 300 mg, Q2W - Cohort 1", "description": "Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks."}, {"id": "OG002", "title": "Tralokinumab 300 mg, Q2/4W - Cohort 2", "description": "Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "151"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.17", "lowerLimit": "0.10", "upperLimit": "0.25"}, {"groupId": "OG001", "value": "0.11", "lowerLimit": "0.06", "upperLimit": "0.17"}, {"groupId": "OG002", "value": "0.10", "lowerLimit": "0.05", "upperLimit": "0.17"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status (atopic/non-atopic), chronic OCS use (presence vs absence) and geographical region as the covariates.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.293", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "0.62", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.26", "ciUpperLimit": "1.51"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status (atopic/non-atopic), chronic OCS use (presence vs absence) and geographical region as the covariates.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.270", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "0.62", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.27", "ciUpperLimit": "1.44"}]}, {"type": "SECONDARY", "title": "Time to First Exacerbation Through Week 53", "description": "Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "populationDescription": "The ITT population included all participants who were randomized into the study.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "days", "timeFrame": "Week 1 up to Week 53", "groups": [{"id": "OG000", "title": "Placebo Total", "description": "Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}, {"id": "OG001", "title": "Tralokinumab 300 mg, Q2W - Cohort 1", "description": "Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks."}, {"id": "OG002", "title": "Tralokinumab 300 mg, Q2/4W - Cohort 2", "description": "Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "151"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "The median and lower and upper limits of the 95% Confidence Interval were incalculable due to an insufficient number of events."}, {"groupId": "OG001", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "The median and lower and upper limits of the 95% Confidence Interval were incalculable due to an insufficient number of events."}, {"groupId": "OG002", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "The median and lower and upper limits of the 95% Confidence Interval were incalculable due to an insufficient number of events."}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.257", "statisticalMethod": "Regression, Cox", "paramType": "Hazard Ratio (HR)", "paramValue": "0.81", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.57", "ciUpperLimit": "1.16"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.225", "statisticalMethod": "Regression, Cox", "paramType": "Hazard Ratio (HR)", "paramValue": "0.80", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.56", "ciUpperLimit": "1.15"}]}, {"type": "SECONDARY", "title": "Time to First Severe Exacerbation Through Week 53", "description": "Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "populationDescription": "The ITT population included all participants who were randomized into the study.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "days", "timeFrame": "Week 1 up to Week 53", "groups": [{"id": "OG000", "title": "Placebo Total", "description": "Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}, {"id": "OG001", "title": "Tralokinumab 300 mg, Q2W - Cohort 1", "description": "Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks."}, {"id": "OG002", "title": "Tralokinumab 300 mg, Q2/4W - Cohort 2", "description": "Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "151"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "The median and lower and upper limits of the 95% Confidence Interval were incalculable due to an insufficient number of events."}, {"groupId": "OG001", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "The median and lower and upper limits of the 95% Confidence Interval were incalculable due to an insufficient number of events."}, {"groupId": "OG002", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "The median and lower and upper limits of the 95% Confidence Interval were incalculable due to an insufficient number of events."}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.538", "statisticalMethod": "Regression, Cox", "paramType": "Hazard Ratio (HR)", "paramValue": "0.79", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.37", "ciUpperLimit": "1.68"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.561", "statisticalMethod": "Regression, Cox", "paramType": "Hazard Ratio (HR)", "paramValue": "0.80", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.37", "ciUpperLimit": "1.71"}]}, {"type": "SECONDARY", "title": "Annual Asthma Exacerbation Rate (AER) by Baseline Serum Periostin", "description": "Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. AER was evaluated by subgroup baseline serum periostin greater than or equal to (\\>=) or less than (\\<) median, \\>= or \\< 25th percentile and \\>= or \\< 75th percentile. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "populationDescription": "The ITT population included all participants who were randomized into the study. Here \"n\" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "AER events/person-year", "timeFrame": "Week 1 up to Week 53", "groups": [{"id": "OG000", "title": "Placebo Total", "description": "Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}, {"id": "OG001", "title": "Tralokinumab 300 mg, Q2W - Cohort 1", "description": "Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks."}, {"id": "OG002", "title": "Tralokinumab 300 mg, Q2/4W - Cohort 2", "description": "Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "151"}]}], "classes": [{"title": ">= median (n=67,81,79)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.13", "lowerLimit": "0.88", "upperLimit": "1.43"}, {"groupId": "OG001", "value": "0.85", "lowerLimit": "0.65", "upperLimit": "1.08"}, {"groupId": "OG002", "value": "1.27", "lowerLimit": "1.03", "upperLimit": "1.55"}]}]}, {"title": "< median (n=84,69,71)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.73", "lowerLimit": "0.55", "upperLimit": "0.95"}, {"groupId": "OG001", "value": "0.98", "lowerLimit": "0.76", "upperLimit": "1.25"}, {"groupId": "OG002", "value": "0.63", "lowerLimit": "0.45", "upperLimit": "0.85"}]}]}, {"title": ">= 25th Percentile (n=105,115,119)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.94", "lowerLimit": "0.75", "upperLimit": "1.15"}, {"groupId": "OG001", "value": "0.84", "lowerLimit": "0.67", "upperLimit": "1.03"}, {"groupId": "OG002", "value": "1.05", "lowerLimit": "0.87", "upperLimit": "1.25"}]}]}, {"title": "< 25th Percentile (n=46,35,31)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.83", "lowerLimit": "0.58", "upperLimit": "1.16"}, {"groupId": "OG001", "value": "1.14", "lowerLimit": "0.81", "upperLimit": "1.56"}, {"groupId": "OG002", "value": "0.65", "lowerLimit": "0.38", "upperLimit": "1.05"}]}]}, {"title": ">= 75th Percentile (n=32,43,39)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.13", "lowerLimit": "0.76", "upperLimit": "1.60"}, {"groupId": "OG001", "value": "0.91", "lowerLimit": "0.65", "upperLimit": "1.25"}, {"groupId": "OG002", "value": "2.03", "lowerLimit": "1.60", "upperLimit": "2.55"}]}]}, {"title": "< 75th Percentile (n=119,107,111)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.85", "lowerLimit": "0.69", "upperLimit": "1.04"}, {"groupId": "OG001", "value": "0.91", "lowerLimit": "0.73", "upperLimit": "1.11"}, {"groupId": "OG002", "value": "0.60", "lowerLimit": "0.46", "upperLimit": "0.77"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline serum periostin \\>= median", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.190", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "0.73", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.46", "ciUpperLimit": "1.17", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline serum periostin \\>= median", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.856", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "0.95", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.56", "ciUpperLimit": "1.61", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline serum periostin \\< median", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.602", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "1.13", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.71", "ciUpperLimit": "1.81", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline serum periostin \\< median", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.703", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "0.91", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.55", "ciUpperLimit": "1.50", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline serum periostin \\>= 25th Percentile", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.455", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "0.86", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.58", "ciUpperLimit": "1.28", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline serum periostin \\>= 25th Percentile", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.929", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "1.02", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.66", "ciUpperLimit": "1.57", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline serum periostin \\< 25th Percentile", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.507", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "1.26", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.63", "ciUpperLimit": "2.51", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline serum periostin \\< 25th Percentile", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.805", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "0.91", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.44", "ciUpperLimit": "1.89", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline serum periostin \\>= 75th Percentile", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.716", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "0.88", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.44", "ciUpperLimit": "1.75", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline serum periostin \\>= 75th Percentile", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.328", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "1.51", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.66", "ciUpperLimit": "3.43", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline serum periostin \\< 75th Percentile", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.804", "statisticalMethod": "Poission regression", "paramType": "Rate Ratio", "paramValue": "0.95", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.64", "ciUpperLimit": "1.41", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline serum periostin \\< 75th Percentile", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.088", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "0.70", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.47", "ciUpperLimit": "1.05", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}]}, {"type": "SECONDARY", "title": "Annual Asthma Exacerbation Rate (AER) by T-helper-2 (Th2) Status", "description": "Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. AER was evaluated by subgroup Th2 status. Th2-high included those participants who had immunoglobulin E (IgE) \\>100 international unit per milliliter (IU/mL) and blood eosinophils \\>= 0.14 \\* 10 power 9 per Liter. Th2 low would include those participants who do not meet Th2 high status. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "populationDescription": "The ITT population included all participants who were randomized into the study. Here \"n\" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "AER events/person-year", "timeFrame": "Week 1 up to Week 53", "groups": [{"id": "OG000", "title": "Placebo Total", "description": "Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}, {"id": "OG001", "title": "Tralokinumab 300 mg, Q2W - Cohort 1", "description": "Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks."}, {"id": "OG002", "title": "Tralokinumab 300 mg, Q2/4W - Cohort 2", "description": "Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "151"}]}], "classes": [{"title": "Th2 high (n=70,74,67)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.96", "lowerLimit": "0.74", "upperLimit": "1.23"}, {"groupId": "OG001", "value": "0.94", "lowerLimit": "0.73", "upperLimit": "1.20"}, {"groupId": "OG002", "value": "1.09", "lowerLimit": "0.85", "upperLimit": "1.39"}]}]}, {"title": "Th2 Low (n=73,61,72)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.90", "lowerLimit": "0.69", "upperLimit": "1.16"}, {"groupId": "OG001", "value": "0.88", "lowerLimit": "0.66", "upperLimit": "1.16"}, {"groupId": "OG002", "value": "0.85", "lowerLimit": "0.64", "upperLimit": "1.11"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Th2 high", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.365", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "0.80", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.50", "ciUpperLimit": "1.29", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Th2 high", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.922", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "0.97", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.56", "ciUpperLimit": "1.68", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Th2 Low", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.685", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "1.11", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.67", "ciUpperLimit": "1.84", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Th2 Low", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.813", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "1.06", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.66", "ciUpperLimit": "1.70", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}]}, {"type": "SECONDARY", "title": "Annual Asthma Exacerbation Rate (AER) by Baseline Peripheral Blood Eosinophil Count", "description": "Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. AER evaluated by subgroups baseline peripheral blood eosinophil counts. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "populationDescription": "The ITT population included all participants who were randomized into the study. Here \"n\" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "AER events/person-year", "timeFrame": "Week 1 up to Week 53", "groups": [{"id": "OG000", "title": "Placebo Total", "description": "Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}, {"id": "OG001", "title": "Tralokinumab 300 mg, Q2W - Cohort 1", "description": "Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks."}, {"id": "OG002", "title": "Tralokinumab 300 mg, Q2/4W - Cohort 2", "description": "Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "151"}]}], "classes": [{"title": ">= 150 cells/mcgL (n=95,104,92)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.95", "lowerLimit": "0.76", "upperLimit": "1.18"}, {"groupId": "OG001", "value": "0.84", "lowerLimit": "0.66", "upperLimit": "1.04"}, {"groupId": "OG002", "value": "0.96", "lowerLimit": "0.77", "upperLimit": "1.19"}]}]}, {"title": "< 150 cells/mcgL (n=48,38,52)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.90", "lowerLimit": "0.64", "upperLimit": "1.22"}, {"groupId": "OG001", "value": "1.09", "lowerLimit": "0.78", "upperLimit": "1.48"}, {"groupId": "OG002", "value": "0.95", "lowerLimit": "0.69", "upperLimit": "1.27"}]}]}, {"title": ">= 300 cells/mcgL (n=54,60,50)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.00", "lowerLimit": "0.74", "upperLimit": "1.32"}, {"groupId": "OG001", "value": "1.01", "lowerLimit": "0.76", "upperLimit": "1.31"}, {"groupId": "OG002", "value": "1.56", "lowerLimit": "1.23", "upperLimit": "1.97"}]}]}, {"title": "< 300 cells/mcgL (n=89,82,94)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.89", "lowerLimit": "0.70", "upperLimit": "1.12"}, {"groupId": "OG001", "value": "0.83", "lowerLimit": "0.64", "upperLimit": "1.06"}, {"groupId": "OG002", "value": "0.63", "lowerLimit": "0.47", "upperLimit": "0.82"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline eosinophil count \\>=150 cells/mcgL", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.335", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "0.82", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.56", "ciUpperLimit": "1.22", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline eosinophil count \\>=150 cells/mcgL", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.586", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "0.88", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.54", "ciUpperLimit": "1.41", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline eosinophil count \\<150 cells/mcgL", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.331", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "1.36", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.73", "ciUpperLimit": "2.52", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline eosinophil count \\<150 cells/mcgL", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.311", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "1.41", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.73", "ciUpperLimit": "2.71", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline eosinophil count \\>=300 cells/mcgL", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.414", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "0.81", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.48", "ciUpperLimit": "1.35", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline eosinophil count \\>=300 cells/mcgL", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.463", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "1.26", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.68", "ciUpperLimit": "2.36", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline eosinophil count \\<300 cells/mcgL", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.793", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "1.06", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.67", "ciUpperLimit": "1.68", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline eosinophil count \\<300 cells/mcgL", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.264", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "0.77", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.49", "ciUpperLimit": "1.22", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}]}, {"type": "SECONDARY", "title": "Annual Asthma Exacerbation Rate (AER) by Baseline FEV1 Reversibility", "description": "Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. AER evaluated by subgroup baseline FEV1 reversibility \\>=12% and \\<12%. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "populationDescription": "The ITT population included all participants who were randomized into the study. Here \"n\" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "AER events/person-year", "timeFrame": "Week 1 up to Week 53", "groups": [{"id": "OG000", "title": "Placebo Total", "description": "Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}, {"id": "OG001", "title": "Tralokinumab 300 mg, Q2W - Cohort 1", "description": "Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks."}, {"id": "OG002", "title": "Tralokinumab 300 mg, Q2/4W - Cohort 2", "description": "Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "151"}]}], "classes": [{"title": "Reversibility >=12% (n=57,43,49)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.88", "lowerLimit": "0.65", "upperLimit": "1.18"}, {"groupId": "OG001", "value": "0.68", "lowerLimit": "0.45", "upperLimit": "0.99"}, {"groupId": "OG002", "value": "1.08", "lowerLimit": "0.80", "upperLimit": "1.42"}]}]}, {"title": "Reversibility <12% (n=91,101,97)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.93", "lowerLimit": "0.73", "upperLimit": "1.16"}, {"groupId": "OG001", "value": "0.99", "lowerLimit": "0.80", "upperLimit": "1.21"}, {"groupId": "OG002", "value": "0.90", "lowerLimit": "0.71", "upperLimit": "1.12"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline FEV1 reversibility \\>=12%", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.245", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "0.66", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.33", "ciUpperLimit": "1.32", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline FEV1 reversibility \\>=12%", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.438", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "0.76", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.37", "ciUpperLimit": "1.54", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline FEV1 reversibility \\<12%", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.947", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "1.01", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.66", "ciUpperLimit": "1.57", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline FEV1 reversibility \\<12%", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.916", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "0.97", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.59", "ciUpperLimit": "1.59", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}]}, {"type": "SECONDARY", "title": "Annual Asthma Exacerbation Rate (AER) by Baseline FEV1% Predicted", "description": "Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. AER was evaluated by subgroup baseline FEV1% predicaed. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "populationDescription": "The ITT population included all participants who were randomized into the study. Here \"n\" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "AER events/person-year", "timeFrame": "Week 1 up to Week 53", "groups": [{"id": "OG000", "title": "Placebo Total", "description": "Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}, {"id": "OG001", "title": "Tralokinumab 300 mg, Q2W - Cohort 1", "description": "Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks."}, {"id": "OG002", "title": "Tralokinumab 300 mg, Q2/4W - Cohort 2", "description": "Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "151"}]}], "classes": [{"title": "FEV1% Predicted <=60% (n=49,45,56)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.05", "lowerLimit": "0.77", "upperLimit": "1.40"}, {"groupId": "OG001", "value": "0.95", "lowerLimit": "0.68", "upperLimit": "1.29"}, {"groupId": "OG002", "value": "1.67", "lowerLimit": "1.34", "upperLimit": "2.07"}]}]}, {"title": "FEV1% Predicted <=80% (n=119,109,105)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.93", "lowerLimit": "0.76", "upperLimit": "1.13"}, {"groupId": "OG001", "value": "0.88", "lowerLimit": "0.71", "upperLimit": "1.08"}, {"groupId": "OG002", "value": "1.13", "lowerLimit": "0.93", "upperLimit": "1.36"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline FEV1% predicted \\<=60%", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.723", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "0.91", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.52", "ciUpperLimit": "1.56", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline FEV1% predicted \\<=60%", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.852", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "1.06", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.60", "ciUpperLimit": "1.86", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline FEV1% predicted \\<=80%", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.409", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "0.86", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.60", "ciUpperLimit": "1.23", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline FEV1% predicted \\<=80%", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.744", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "1.07", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.72", "ciUpperLimit": "1.58", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}]}, {"type": "SECONDARY", "title": "Annual Asthma Exacerbation Rate (AER) by Asthma Exacerbations in the Past Year", "description": "Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. AER evaluated by subgroup as asthma exacerbations in the past year. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "populationDescription": "The ITT population included all participants who were randomized into the study. Here \"n\" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "AER events/person-year", "timeFrame": "Week 1 up to Week 53", "groups": [{"id": "OG000", "title": "Placebo Total", "description": "Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}, {"id": "OG001", "title": "Tralokinumab 300 mg, Q2W - Cohort 1", "description": "Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks."}, {"id": "OG002", "title": "Tralokinumab 300 mg, Q2/4W - Cohort 2", "description": "Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "151"}]}], "classes": [{"title": "2 asthma exacerbations (n=97,96,95)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.62", "lowerLimit": "0.47", "upperLimit": "0.81"}, {"groupId": "OG001", "value": "0.61", "lowerLimit": "0.45", "upperLimit": "0.79"}, {"groupId": "OG002", "value": "0.45", "lowerLimit": "0.32", "upperLimit": "0.61"}]}]}, {"title": "> 2 but < 6 asthma exacerbations (n=54,54,56)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.44", "lowerLimit": "1.12", "upperLimit": "1.82"}, {"groupId": "OG001", "value": "1.42", "lowerLimit": "1.12", "upperLimit": "1.78"}, {"groupId": "OG002", "value": "1.88", "lowerLimit": "1.52", "upperLimit": "2.30"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "2 asthma exacerbations in the past year", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.802", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "0.94", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.58", "ciUpperLimit": "1.52", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}, {"groupIds": ["OG000", "OG002"], "groupDescription": "2 asthma exacerbations in the past year", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.050", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "0.60", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.36", "ciUpperLimit": "1.00", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "\\> 2 but \\< 6 asthma exacerbations in the past year", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.792", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "0.93", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.56", "ciUpperLimit": "1.56", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}, {"groupIds": ["OG000", "OG002"], "groupDescription": "\\> 2 but \\< 6 asthma exacerbations in the past year", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.231", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "1.39", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.81", "ciUpperLimit": "2.38", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}]}, {"type": "SECONDARY", "title": "Severe Asthma Exacerbation Rate (AER) by Baseline Serum Periostin", "description": "Severe AER was assessed based on AER data up to Week 53. Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. Severe AER evaluated by subgroup baseline serum periostin. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "populationDescription": "The ITT population included all participants who were randomized into the study. Here \"n\" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "AER events/person-year", "timeFrame": "Week 1 up to Week 53", "groups": [{"id": "OG000", "title": "Placebo Total", "description": "Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}, {"id": "OG001", "title": "Tralokinumab 300 mg, Q2W - Cohort 1", "description": "Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks."}, {"id": "OG002", "title": "Tralokinumab 300 mg, Q2/4W - Cohort 2", "description": "Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "151"}]}], "classes": [{"title": ">= median (n=67,81,79)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.25", "lowerLimit": "0.14", "upperLimit": "0.40"}, {"groupId": "OG001", "value": "0.08", "lowerLimit": "0.03", "upperLimit": "0.17"}, {"groupId": "OG002", "value": "0.12", "lowerLimit": "0.06", "upperLimit": "0.23"}]}]}, {"title": "< median (n=84,69,71)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.10", "lowerLimit": "0.04", "upperLimit": "0.20"}, {"groupId": "OG001", "value": "0.14", "lowerLimit": "0.06", "upperLimit": "0.26"}, {"groupId": "OG002", "value": "0.08", "lowerLimit": "0.03", "upperLimit": "0.18"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline Serum Periostin \\>=Median", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.046", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "0.25", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.06", "ciUpperLimit": "0.98", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline Serum Periostin \\>=Median", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.197", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "0.47", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.15", "ciUpperLimit": "1.48", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline Serum Periostin \\< Median", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.708", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "1.18", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.50", "ciUpperLimit": "2.79", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline Serum Periostin \\< Median", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.594", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "1.31", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.48", "ciUpperLimit": "3.57", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}]}, {"type": "SECONDARY", "title": "Severe Asthma Exacerbation Rate (AER) by Baseline FEV1 Reversibility", "description": "Severe AER was assessed based on AER data up to Week 53. Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. Severe AER was evaluated by subgroup FEV1 reversibility. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "populationDescription": "The ITT population included all participants who were randomized into the study. Here \"n\" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "AER events/person-year", "timeFrame": "Week 1 up to Week 53", "groups": [{"id": "OG000", "title": "Placebo Total", "description": "Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}, {"id": "OG001", "title": "Tralokinumab 300 mg, Q2W - Cohort 1", "description": "Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks."}, {"id": "OG002", "title": "Tralokinumab 300 mg, Q2/4W - Cohort 2", "description": "Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "151"}]}], "classes": [{"title": "Reversibility >=12% (n=57,43,49)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.11", "lowerLimit": "0.04", "upperLimit": "0.25"}, {"groupId": "OG001", "value": "0.13", "lowerLimit": "0.04", "upperLimit": "0.29"}, {"groupId": "OG002", "value": "0.13", "lowerLimit": "0.05", "upperLimit": "0.28"}]}]}, {"title": "Reversibility <12% (n=91,101,97)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.20", "lowerLimit": "0.12", "upperLimit": "0.32"}, {"groupId": "OG001", "value": "0.10", "lowerLimit": "0.05", "upperLimit": "0.19"}, {"groupId": "OG002", "value": "0.09", "lowerLimit": "0.04", "upperLimit": "0.18"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline FEV1 reversibility \\>=12%", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.975", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "1.03", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.14", "ciUpperLimit": "7.67", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline FEV1 reversibility \\>=12%", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.473", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "1.66", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.41", "ciUpperLimit": "6.67", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline FEV1 reversibility \\<12%", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.099", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "0.49", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.21", "ciUpperLimit": "1.14", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline FEV1 reversibility \\<12%", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.148", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "0.42", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.13", "ciUpperLimit": "1.36", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}]}, {"type": "SECONDARY", "title": "Severe Asthma Exacerbation Rate (AER) by T-helper-2 (Th2) Status", "description": "Severe AER was assessed based on AER data up to Week 53. An asthma exacerbation is a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 days. It was considered resolved 7 days after last dose of OCS administered (10 days after injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. Severe AER was evaluated by subgroup Th2 status. Th2-high include participants who had IgE \\>100 IU/mL and blood eosinophils \\>=0.14\\*10\\^9/Liter. Th2 low would include participants who do not meet Th2 high status. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "populationDescription": "The ITT population included all participants who were randomized into the study. Here \"n\" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "AER events/person-year", "timeFrame": "Week 1 up to Week 53", "groups": [{"id": "OG000", "title": "Placebo Total", "description": "Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}, {"id": "OG001", "title": "Tralokinumab 300 mg, Q2W - Cohort 1", "description": "Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks."}, {"id": "OG002", "title": "Tralokinumab 300 mg, Q2/4W - Cohort 2", "description": "Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "151"}]}], "classes": [{"title": "Th2 high (n=70,74,67)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.12", "lowerLimit": "0.05", "upperLimit": "0.24"}, {"groupId": "OG001", "value": "0.12", "lowerLimit": "0.05", "upperLimit": "0.23"}, {"groupId": "OG002", "value": "0.06", "lowerLimit": "0.02", "upperLimit": "0.16"}]}]}, {"title": "Th2 Low (n=73,61,72)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.21", "lowerLimit": "0.11", "upperLimit": "0.35"}, {"groupId": "OG001", "value": "0.05", "lowerLimit": "0.01", "upperLimit": "0.15"}, {"groupId": "OG002", "value": "0.12", "lowerLimit": "0.05", "upperLimit": "0.24"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Th2 high", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.698", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "0.82", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.31", "ciUpperLimit": "2.19", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Th2 high", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.299", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "0.55", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.18", "ciUpperLimit": "1.70", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Th2 Low", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.105", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "0.25", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.05", "ciUpperLimit": "1.34", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Th2 Low", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.576", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "0.70", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.20", "ciUpperLimit": "2.47", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}]}, {"type": "SECONDARY", "title": "Severe Asthma Exacerbation Rate (AER) by Baseline Peripheral Blood Eosinophil Count", "description": "Severe AER was assessed based on AER data up to Week 53. Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. Severe AER was evaluated by subgroup baseline peripheral blood eosinophil count. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "populationDescription": "The ITT population included all participants who were randomized into the study. Here \"n\" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "AER events/person-year", "timeFrame": "Week 1 up to Week 53", "groups": [{"id": "OG000", "title": "Placebo Total", "description": "Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}, {"id": "OG001", "title": "Tralokinumab 300 mg, Q2W - Cohort 1", "description": "Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks."}, {"id": "OG002", "title": "Tralokinumab 300 mg, Q2/4W - Cohort 2", "description": "Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "151"}]}], "classes": [{"title": ">= 300 cells/mcgL (n=54,60,50)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.22", "lowerLimit": "0.11", "upperLimit": "0.40"}, {"groupId": "OG001", "value": "0.16", "lowerLimit": "0.07", "upperLimit": "0.31"}, {"groupId": "OG002", "value": "0.15", "lowerLimit": "0.06", "upperLimit": "0.31"}]}]}, {"title": "< 300 cells/mcgL (n=89,82,94)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.13", "lowerLimit": "0.07", "upperLimit": "0.24"}, {"groupId": "OG001", "value": "0.08", "lowerLimit": "0.03", "upperLimit": "0.16"}, {"groupId": "OG002", "value": "0.08", "lowerLimit": "0.03", "upperLimit": "0.17"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline eosinophil count \\>=300 cells/mcgL", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.133", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "0.48", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.19", "ciUpperLimit": "1.25", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline eosinophil count \\>=300 cells/mcgL", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.241", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "0.46", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.13", "ciUpperLimit": "1.67", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline eosinophil count \\<300 cells/mcgL", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.510", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "0.59", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.12", "ciUpperLimit": "2.84", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline eosinophil count \\<300 cells/mcgL", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.661", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "0.74", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.19", "ciUpperLimit": "2.85", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Prebronchodilator FEV1 at Week 53 in Subgroups", "description": "Prebronchodilator FEV1 was evaluated by subgroups. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "populationDescription": "The ITT population included all participants who were randomized into the study. Here \"n\" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percent change", "timeFrame": "Week 1 up to Week 53", "groups": [{"id": "OG000", "title": "Placebo Total", "description": "Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}, {"id": "OG001", "title": "Tralokinumab 300 mg, Q2W - Cohort 1", "description": "Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks."}, {"id": "OG002", "title": "Tralokinumab 300 mg, Q2/4W - Cohort 2", "description": "Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "151"}]}], "classes": [{"title": "Baseline SP >=median (n=54,71,65)", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.17", "spread": "2.75", "lowerLimit": "0.88", "upperLimit": "1.43"}, {"groupId": "OG001", "value": "10.48", "spread": "3.01", "lowerLimit": "0.65", "upperLimit": "1.08"}, {"groupId": "OG002", "value": "4.36", "spread": "2.25", "lowerLimit": "1.03", "upperLimit": "1.55"}]}]}, {"title": "Baseline SP <median (n=71,59,56)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.23", "spread": "2.82", "lowerLimit": "0.55", "upperLimit": "0.95"}, {"groupId": "OG001", "value": "7.46", "spread": "3.00", "lowerLimit": "0.76", "upperLimit": "1.25"}, {"groupId": "OG002", "value": "1.30", "spread": "2.12", "lowerLimit": "0.45", "upperLimit": "0.85"}]}]}, {"title": "Baseline SP >=25th Percentile (n=88,102,100)", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.10", "spread": "2.29", "lowerLimit": "0.75", "upperLimit": "1.15"}, {"groupId": "OG001", "value": "10.40", "spread": "2.43", "lowerLimit": "0.67", "upperLimit": "1.03"}, {"groupId": "OG002", "value": "2.31", "spread": "1.66", "lowerLimit": "0.87", "upperLimit": "1.25"}]}]}, {"title": "Baseline SP <25th Percentile (n=37,28,21)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.29", "spread": "3.92", "lowerLimit": "0.58", "upperLimit": "1.16"}, {"groupId": "OG001", "value": "4.40", "spread": "4.39", "lowerLimit": "0.81", "upperLimit": "1.56"}, {"groupId": "OG002", "value": "5.99", "spread": "4.22", "lowerLimit": "0.38", "upperLimit": "1.05"}]}]}, {"title": "Baseline SP >=75th Percentile (n=25,40,32)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.32", "spread": "4.07", "lowerLimit": "0.76", "upperLimit": "1.60"}, {"groupId": "OG001", "value": "11.05", "spread": "4.67", "lowerLimit": "0.65", "upperLimit": "1.25"}, {"groupId": "OG002", "value": "2.97", "spread": "3.33", "lowerLimit": "1.60", "upperLimit": "2.55"}]}]}, {"title": "Baseline SP <75th Percentile (n=100,90,89)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.55", "spread": "2.28", "lowerLimit": "0.69", "upperLimit": "1.04"}, {"groupId": "OG001", "value": "8.25", "spread": "2.29", "lowerLimit": "0.73", "upperLimit": "1.11"}, {"groupId": "OG002", "value": "2.94", "spread": "1.75", "lowerLimit": "0.46", "upperLimit": "0.77"}]}]}, {"title": "Th2 high (n=63,62,57)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.10", "spread": "2.62"}, {"groupId": "OG001", "value": "11.62", "spread": "3.23"}, {"groupId": "OG002", "value": "4.52", "spread": "2.39"}]}]}, {"title": "Th2 low (n=57,55,55)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.90", "spread": "3.09"}, {"groupId": "OG001", "value": "3.87", "spread": "2.50"}, {"groupId": "OG002", "value": "0.13", "spread": "1.72"}]}]}, {"title": "Baseline PBEC >=150 cells/mcgL (n=81,89,75)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.98", "spread": "2.32"}, {"groupId": "OG001", "value": "10.97", "spread": "2.71"}, {"groupId": "OG002", "value": "4.67", "spread": "2.17"}]}]}, {"title": "Baseline PBEC <150 cells/mcgL (n=39,34,40)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.05", "spread": "3.89"}, {"groupId": "OG001", "value": "5.75", "spread": "3.75"}, {"groupId": "OG002", "value": "-0.40", "spread": "2.00"}]}]}, {"title": "Baseline PBEC >=300 cells/mcgL (n=45,51,39)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.59", "spread": "2.88"}, {"groupId": "OG001", "value": "14.04", "spread": "3.88"}, {"groupId": "OG002", "value": "4.65", "spread": "2.90"}]}]}, {"title": "Baseline PBEC <300 cells/mcgL (n=75,72,76)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.85", "spread": "2.71"}, {"groupId": "OG001", "value": "6.33", "spread": "2.57"}, {"groupId": "OG002", "value": "2.01", "spread": "1.89"}]}]}, {"title": "Baseline FEV1 reversibility >=12% (n=49,36,41)", "categories": [{"measurements": [{"groupId": "OG000", "value": "11.02", "spread": "3.85"}, {"groupId": "OG001", "value": "22.78", "spread": "5.20"}, {"groupId": "OG002", "value": "11.80", "spread": "3.48"}]}]}, {"title": "Baseline FEV1 reversibility <12% (n=76,92,80)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.99", "spread": "1.90"}, {"groupId": "OG001", "value": "3.98", "spread": "1.97"}, {"groupId": "OG002", "value": "-1.66", "spread": "1.28"}]}]}, {"title": "2 asthma exacerbations (n=84,81,82)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.76", "spread": "2.16"}, {"groupId": "OG001", "value": "8.99", "spread": "2.41"}, {"groupId": "OG002", "value": "3.57", "spread": "2.04"}]}]}, {"title": "> 2 but < 6 asthma exacerbations (n=41,49,40)", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.08", "spread": "4.12"}, {"groupId": "OG001", "value": "9.32", "spread": "4.05"}, {"groupId": "OG002", "value": "1.63", "spread": "2.17"}]}]}, {"title": "Chronic OCS use (n=20,21,16)", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.44", "spread": "5.82"}, {"groupId": "OG001", "value": "6.96", "spread": "6.56"}, {"groupId": "OG002", "value": "-0.48", "spread": "5.31"}]}]}, {"title": "Without chronic OCS use (n=105,109,106)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.32", "spread": "2.10"}, {"groupId": "OG001", "value": "9.52", "spread": "2.22"}, {"groupId": "OG002", "value": "3.45", "spread": "1.59"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline serum periostin \\>= median", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.057", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "6.79", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.21", "ciUpperLimit": "13.79"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline serum periostin \\>= median", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.874", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "0.57", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-6.54", "ciUpperLimit": "7.68"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline serum periostin \\< median", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.028", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "7.37", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.80", "ciUpperLimit": "13.95"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline serum periostin \\< median", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.745", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "1.09", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.48", "ciUpperLimit": "7.66"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline serum periostin \\>= 25th percentile", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.011", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "7.12", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.66", "ciUpperLimit": "12.58"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline serum periostin \\>= 25th percentile", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.863", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "-0.48", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.93", "ciUpperLimit": "4.97"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline serum periostin \\< 25th percentile", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.221", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "6.24", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.80", "ciUpperLimit": "16.27"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline serum periostin \\< 25th percentile", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.108", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "8.58", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.91", "ciUpperLimit": "19.07"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline serum periostin \\>= 75th percentile", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.090", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "9.89", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.57", "ciUpperLimit": "21.35"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline serum periostin \\>= 75th percentile", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.908", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "0.70", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-11.19", "ciUpperLimit": "12.59"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline serum periostin \\< 75th percentile", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.013", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "6.52", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.41", "ciUpperLimit": "11.64"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline serum periostin \\< 75th percentile", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.635", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "1.23", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.84", "ciUpperLimit": "6.29"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Th2 high", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.014", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "8.89", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.84", "ciUpperLimit": "15.94"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Th2 high", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.280", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "3.91", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.19", "ciUpperLimit": "11.02"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Th2 low", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.292", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "3.22", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.78", "ciUpperLimit": "9.22"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Th2 low", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.691", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "-1.18", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-6.99", "ciUpperLimit": "4.64"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline peripheral blood eosinophil count \\>= 150 cells/\u03bcL", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.004", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "8.83", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "2.85", "ciUpperLimit": "14.81"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline peripheral blood eosinophil count \\>= 150 cells/\u03bcL", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.177", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "4.25", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.92", "ciUpperLimit": "10.43"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline peripheral blood eosinophil count \\< 150 cells/\u03bcL", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.159", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "6.05", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.39", "ciUpperLimit": "14.50"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline peripheral blood eosinophil count \\< 150 cells/\u03bcL", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.857", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "-0.72", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-8.63", "ciUpperLimit": "7.18"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline peripheral blood eosinophil count \\>= 300 cells/\u03bcL", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.002", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "13.75", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "5.28", "ciUpperLimit": "22.22"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline peripheral blood eosinophil count \\>= 300 cells/\u03bcL", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.243", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "5.23", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.56", "ciUpperLimit": "14.02"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline peripheral blood eosinophil count \\< 300 cells/\u03bcL", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.144", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "4.37", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.50", "ciUpperLimit": "10.24"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline peripheral blood eosinophil count \\< 300 cells/\u03bc", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.804", "statisticalMethod": "Baseline peripheral blood eosinophil cou", "paramType": "Difference of LS-mean", "paramValue": "0.72", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.01", "ciUpperLimit": "6.46"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline FEV1 reversibility \\>= 12%", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.029", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "11.19", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.15", "ciUpperLimit": "21.23"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline FEV1 reversibility \\>= 12%", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.887", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "0.72", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-9.19", "ciUpperLimit": "10.62"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline FEV1 reversibility \\< 12%", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.002", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "7.67", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "2.76", "ciUpperLimit": "12.59"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline FEV1 reversibility \\< 12%", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.268", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "2.79", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.15", "ciUpperLimit": "7.74"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "2 asthma exacerbations in the past year", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.003", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "7.82", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "2.64", "ciUpperLimit": "13.01"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "2 asthma exacerbations in the past year", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.361", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "2.42", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.78", "ciUpperLimit": "7.62"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "\\> 2 but \\< 6 asthma exacerbations in the past year", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.185", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "6.34", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.06", "ciUpperLimit": "15.75"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "\\> 2 but \\< 6 asthma exacerbations in the past year", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.986", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "-0.08", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-9.50", "ciUpperLimit": "9.34"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Chronic OCS use", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.912", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "0.87", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-14.70", "ciUpperLimit": "16.44"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Chronic OCS use", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.860", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "-1.46", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-17.76", "ciUpperLimit": "14.84"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Without chronic OCS use", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.002", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "7.56", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "2.76", "ciUpperLimit": "12.36"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Without chronic OCS use", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.601", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "1.28", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.51", "ciUpperLimit": "6.06"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean ACQ-6 Scores at Week 53 in Subgroups", "description": "Asthma Control Questionnaire (ACQ) is a participant-reported questionnaire to assess the asthma control with 6 items assessing night-time waking, symptoms on waking, activity limitation, shortness of breath, wheeze, and rescue short-acting beta agonist use. Each item was rated on a 7-point Likert scale ranging from 0 (no impairment) to 6 (maximum impairment). Overall ACQ score was the mean of the 6 item scores with a score range of 0 (well controlled) to 6 (extremely poor controlled). Data collected on Day 1 prior to dosing was considered as baseline. Results were reported for overall ACQ score. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "populationDescription": "The ITT population included all participants who were randomized into the study. Here \"n\" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Week 1 up to Week 53", "groups": [{"id": "OG000", "title": "Placebo Total", "description": "Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}, {"id": "OG001", "title": "Tralokinumab 300 mg, Q2W - Cohort 1", "description": "Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks."}, {"id": "OG002", "title": "Tralokinumab 300 mg, Q2/4W - Cohort 2", "description": "Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "151"}]}], "classes": [{"title": "Baseline SP >= Median (n= 51, 65, 60)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.88", "spread": "0.15", "lowerLimit": "0.88", "upperLimit": "1.43"}, {"groupId": "OG001", "value": "-1.18", "spread": "0.13", "lowerLimit": "0.65", "upperLimit": "1.08"}, {"groupId": "OG002", "value": "-0.85", "spread": "0.14", "lowerLimit": "1.03", "upperLimit": "1.55"}]}]}, {"title": "Baseline SP < Median (n= 67, 50, 52)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.77", "spread": "0.14", "lowerLimit": "0.55", "upperLimit": "0.95"}, {"groupId": "OG001", "value": "-0.81", "spread": "0.15", "lowerLimit": "0.76", "upperLimit": "1.25"}, {"groupId": "OG002", "value": "-1.03", "spread": "0.17", "lowerLimit": "0.45", "upperLimit": "0.85"}]}]}, {"title": "Baseline SP >= 25th Percentile (n= 82, 92, 91)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.86", "spread": "0.12", "lowerLimit": "0.75", "upperLimit": "1.15"}, {"groupId": "OG001", "value": "-1.04", "spread": "0.11", "lowerLimit": "0.67", "upperLimit": "1.03"}, {"groupId": "OG002", "value": "-0.93", "spread": "0.13", "lowerLimit": "0.87", "upperLimit": "1.25"}]}]}, {"title": "Baseline SP < 25th Percentile (n= 36, 23, 21)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.73", "spread": "0.19", "lowerLimit": "0.58", "upperLimit": "1.16"}, {"groupId": "OG001", "value": "-0.95", "spread": "0.24", "lowerLimit": "0.81", "upperLimit": "1.56"}, {"groupId": "OG002", "value": "-0.92", "spread": "0.24", "lowerLimit": "0.38", "upperLimit": "1.05"}]}]}, {"title": "Baseline SP >= 75th Percentile (n= 25, 34, 27)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.75", "spread": "0.14", "lowerLimit": "0.76", "upperLimit": "1.60"}, {"groupId": "OG001", "value": "-1.25", "spread": "0.18", "lowerLimit": "0.65", "upperLimit": "1.25"}, {"groupId": "OG002", "value": "-1.01", "spread": "0.23", "lowerLimit": "1.60", "upperLimit": "2.55"}]}]}, {"title": "Baseline SP < 75th Percentile (n= 93, 81, 85)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.84", "spread": "0.12", "lowerLimit": "0.69", "upperLimit": "1.04"}, {"groupId": "OG001", "value": "-0.92", "spread": "0.12", "lowerLimit": "0.73", "upperLimit": "1.11"}, {"groupId": "OG002", "value": "-0.91", "spread": "0.13", "lowerLimit": "0.46", "upperLimit": "0.77"}]}]}, {"title": "Th2 High (n= 59, 56, 55)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.95", "spread": "0.13"}, {"groupId": "OG001", "value": "-1.10", "spread": "0.15"}, {"groupId": "OG002", "value": "-1.02", "spread": "0.15"}]}]}, {"title": "Th2 Low (n= 55, 47, 50)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.70", "spread": "0.16"}, {"groupId": "OG001", "value": "-0.94", "spread": "0.14"}, {"groupId": "OG002", "value": "-0.87", "spread": "0.17"}]}]}, {"title": "Baseline EC >= 150 Cells/UL (n= 77, 78, 70)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.84", "spread": "0.13"}, {"groupId": "OG001", "value": "-1.07", "spread": "0.13"}, {"groupId": "OG002", "value": "-0.94", "spread": "0.13"}]}]}, {"title": "Baseline EC < 150 Cells/UL (n= 37, 31, 37)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.81", "spread": "0.18"}, {"groupId": "OG001", "value": "-0.92", "spread": "0.16"}, {"groupId": "OG002", "value": "-1.02", "spread": "0.21"}]}]}, {"title": "Baseline EC >= 300 Cells/UL (n= 43, 44, 37)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.77", "spread": "0.15"}, {"groupId": "OG001", "value": "-1.24", "spread": "0.16"}, {"groupId": "OG002", "value": "-0.91", "spread": "0.17"}]}]}, {"title": "Baseline EC < 300 Cells/UL (n= 71, 65, 70)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.86", "spread": "0.14"}, {"groupId": "OG001", "value": "-0.88", "spread": "0.12"}, {"groupId": "OG002", "value": "-1.00", "spread": "0.15"}]}]}, {"title": "Baseline FEV1 Reversibility >= 12% (n= 43, 33, 35)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.47", "spread": "0.19"}, {"groupId": "OG001", "value": "-0.90", "spread": "0.18"}, {"groupId": "OG002", "value": "-0.76", "spread": "0.20"}]}]}, {"title": "Baseline FEV1 Reversibility < 12% (n= 73, 78, 75)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.03", "spread": "0.11"}, {"groupId": "OG001", "value": "-1.12", "spread": "0.12"}, {"groupId": "OG002", "value": "-1.02", "spread": "0.13"}]}]}, {"title": "2 Asthma Exacerbations (n= 79, 72, 75)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.77", "spread": "0.13"}, {"groupId": "OG001", "value": "-0.94", "spread": "0.13"}, {"groupId": "OG002", "value": "-0.95", "spread": "0.14"}]}]}, {"title": ">2 Asthma Exacerbations (n= 39, 43, 37)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.93", "spread": "0.17"}, {"groupId": "OG001", "value": "-1.15", "spread": "0.15"}, {"groupId": "OG002", "value": "-0.90", "spread": "0.19"}]}]}, {"title": "With Chronic OCS Use (n= 20, 17, 18)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.39", "spread": "0.25"}, {"groupId": "OG001", "value": "-0.89", "spread": "0.28"}, {"groupId": "OG002", "value": "-0.16", "spread": "0.23"}]}]}, {"title": "Without Chronic OCS Use (n= 98, 98, 94)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.91", "spread": "0.11"}, {"groupId": "OG001", "value": "-1.04", "spread": "0.11"}, {"groupId": "OG002", "value": "-1.08", "spread": "0.12"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline serum periostin \\>= median", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.145", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "-0.24", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.57", "ciUpperLimit": "0.08"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline serum periostin \\>= median", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.759", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "0.05", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.28", "ciUpperLimit": "0.38"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline serum periostin \\< median", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.936", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "-0.01", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.38", "ciUpperLimit": "0.35"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline serum periostin \\< median", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.127", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "-0.28", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.64", "ciUpperLimit": "0.08"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline serum periostin\\>= 25th percentile", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.343", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "-0.13", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.41", "ciUpperLimit": "0.14"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline serum periostin\\>= 25th percentile", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.928", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "-0.01", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.29", "ciUpperLimit": "0.27"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline serum periostin \\< 25th percentile", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.374", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "-0.23", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.74", "ciUpperLimit": "0.28"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline serum periostin \\< 25th percentile", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.259", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "-0.29", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.81", "ciUpperLimit": "0.22"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline serum periostin \\>= 75th percentile", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.127", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "-0.37", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.84", "ciUpperLimit": "0.11"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline serum periostin \\>= 75th percentile", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.775", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "-0.07", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.56", "ciUpperLimit": "0.42"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline serum periostin \\< 75th percentile", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.512", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "-0.10", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.38", "ciUpperLimit": "0.19"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline serum periostin \\< 75th percentile", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.404", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "-0.12", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.40", "ciUpperLimit": "0.16"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Th2 high", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.181", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "-0.24", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.59", "ciUpperLimit": "0.11"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Th2 high", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.161", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "-0.25", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.60", "ciUpperLimit": "0.10"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Th2 low", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.540", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "-0.11", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.47", "ciUpperLimit": "0.25"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Th2 low", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.674", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "-0.07", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.42", "ciUpperLimit": "0.27"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline peripheral blood eosinophil count \\>= 150 cells/\u03bcL", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.154", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "-0.22", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.52", "ciUpperLimit": "0.08"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline peripheral blood eosinophil count \\>= 150 cells/\u03bc", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.271", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "-0.17", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.48", "ciUpperLimit": "0.13"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline peripheral blood eosinophil count \\< 150 cells/\u03bcL", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.725", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "-0.08", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.51", "ciUpperLimit": "0.36"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline peripheral blood eosinophil count \\< 150 cells/\u03bcL", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.559", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "-0.12", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.53", "ciUpperLimit": "0.28"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline peripheral blood eosinophil count \\>= 300 cells/\u03bcL", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.019", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "-0.47", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.87", "ciUpperLimit": "-0.08"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline peripheral blood eosinophil count \\>= 300 cells/\u03bcL", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.348", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "-0.20", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.61", "ciUpperLimit": "0.21"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline peripheral blood eosinophil count \\< 300 cells/\u03bcL", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.855", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "-0.03", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.35", "ciUpperLimit": "0.29"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline peripheral blood eosinophil count \\< 300 cells/\u03bcL", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.203", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "-0.20", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.50", "ciUpperLimit": "0.11"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline FEV1 reversibility \\>= 12%", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.055", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "-0.44", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.89", "ciUpperLimit": "0.01"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline FEV1 reversibility \\>= 12%", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.104", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "-0.37", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.82", "ciUpperLimit": "0.08"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline FEV1 reversibility \\< 12%", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.652", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "-0.07", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.37", "ciUpperLimit": "0.23"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline FEV1 reversibility \\< 12%", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.905", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "0.02", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.28", "ciUpperLimit": "0.32"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "2 asthma exacerbations in the past year", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.198", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "-0.19", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.49", "ciUpperLimit": "0.10"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "2 asthma exacerbations in the past year", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.226", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "-0.18", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.47", "ciUpperLimit": "0.11"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "\\> 2 but \\< 6 asthma exacerbations in the past year", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.513", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "-0.14", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.56", "ciUpperLimit": "0.28"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "\\> 2 but \\< 6 asthma exacerbations in the past year", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.974", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "-0.01", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.43", "ciUpperLimit": "0.42"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Chronic OCS use", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.226", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "-0.37", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.97", "ciUpperLimit": "0.23"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Chronic OCS use", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.613", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "0.15", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.44", "ciUpperLimit": "0.75"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Without chronic OCS use", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.198", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "-0.17", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.43", "ciUpperLimit": "0.09"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Without chronic OCS use", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.165", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "-0.19", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.45", "ciUpperLimit": "0.08"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Total AQLQ(S) Scores at Week 53 in Subgroups", "description": "AQLQ: a 32-item questionnaire evaluating quality of life of participants with asthma including 4 domains (symptoms, activity limitations, emotional function, and environmental stimuli). Participants were asked to recall their experiences during the previous 2 weeks and to score each of the 32 questions on a 7-point scale ranging from 7 (no impairment) to 1 (severe impairment). The overall score was calculated as the mean response to all questions. The 4 domain scores were the means of the responses to the questions in each of the domains. Overall AQLQ score and 4 domain scores ranged from 7 (no impairment) to 1 (severe impairment). Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "populationDescription": "The ITT population included all participants who were randomized into the study. Here \"n\" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Week 1 up to Week 53", "groups": [{"id": "OG000", "title": "Placebo Total", "description": "Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}, {"id": "OG001", "title": "Tralokinumab 300 mg, Q2W - Cohort 1", "description": "Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks."}, {"id": "OG002", "title": "Tralokinumab 300 mg, Q2/4W - Cohort 2", "description": "Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "151"}]}], "classes": [{"title": "Baseline SP >= Median (n= 46, 63, 56)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.89", "spread": "0.15", "lowerLimit": "0.88", "upperLimit": "1.43"}, {"groupId": "OG001", "value": "1.10", "spread": "0.14", "lowerLimit": "0.65", "upperLimit": "1.08"}, {"groupId": "OG002", "value": "0.95", "spread": "0.17", "lowerLimit": "1.03", "upperLimit": "1.55"}]}]}, {"title": "Baseline SP < Median ( n= 61, 46, 45)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.82", "spread": "0.14", "lowerLimit": "0.55", "upperLimit": "0.95"}, {"groupId": "OG001", "value": "0.95", "spread": "0.15", "lowerLimit": "0.76", "upperLimit": "1.25"}, {"groupId": "OG002", "value": "1.07", "spread": "0.17", "lowerLimit": "0.45", "upperLimit": "0.85"}]}]}, {"title": "Baseline SP >= 25th Percentile (n= 73, 88, 82)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.87", "spread": "0.12", "lowerLimit": "0.75", "upperLimit": "1.15"}, {"groupId": "OG001", "value": "1.08", "spread": "0.11", "lowerLimit": "0.67", "upperLimit": "1.03"}, {"groupId": "OG002", "value": "0.98", "spread": "0.14", "lowerLimit": "0.87", "upperLimit": "1.25"}]}]}, {"title": "Baseline SP < 25th Percentile (n= 34, 21, 19)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.81", "spread": "0.19", "lowerLimit": "0.58", "upperLimit": "1.16"}, {"groupId": "OG001", "value": "0.84", "spread": "0.24", "lowerLimit": "0.81", "upperLimit": "1.56"}, {"groupId": "OG002", "value": "1.09", "spread": "0.24", "lowerLimit": "0.38", "upperLimit": "1.05"}]}]}, {"title": "Baseline SP >= 75th Percentile (n= 23, 33, 24)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.76", "spread": "0.17", "lowerLimit": "0.76", "upperLimit": "1.60"}, {"groupId": "OG001", "value": "1.20", "spread": "0.19", "lowerLimit": "0.65", "upperLimit": "1.25"}, {"groupId": "OG002", "value": "1.13", "spread": "0.28", "lowerLimit": "1.60", "upperLimit": "2.55"}]}]}, {"title": "Baseline SP < 75th Percentile (n= 84, 76, 77)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.87", "spread": "0.12", "lowerLimit": "0.69", "upperLimit": "1.04"}, {"groupId": "OG001", "value": "0.97", "spread": "0.12", "lowerLimit": "0.73", "upperLimit": "1.11"}, {"groupId": "OG002", "value": "0.96", "spread": "0.13", "lowerLimit": "0.46", "upperLimit": "0.77"}]}]}, {"title": "Th2 high (n=54,52,50)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.88", "spread": "0.13"}, {"groupId": "OG001", "value": "1.12", "spread": "0.15"}, {"groupId": "OG002", "value": "1.12", "spread": "0.18"}]}]}, {"title": "Th2 low (n= 49, 45, 44 )", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.79", "spread": "0.17"}, {"groupId": "OG001", "value": "0.88", "spread": "0.15"}, {"groupId": "OG002", "value": "0.94", "spread": "0.17"}]}]}, {"title": "Baseline EC >= 150 Cells/UL (n=69, 72, 64)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.91", "spread": "0.11"}, {"groupId": "OG001", "value": "1.06", "spread": "0.13"}, {"groupId": "OG002", "value": "1.02", "spread": "0.15"}]}]}, {"title": "Baseline EC< 150 Cells/UL (n= 34, 31, 32)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.68", "spread": "0.20"}, {"groupId": "OG001", "value": "0.93", "spread": "0.13"}, {"groupId": "OG002", "value": "1.05", "spread": "0.20"}]}]}, {"title": "Baseline EC >= 300 Cells/UL (n= 39, 40, 35)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.81", "spread": "0.15"}, {"groupId": "OG001", "value": "0.98", "spread": "0.17"}, {"groupId": "OG002", "value": "0.82", "spread": "0.20"}]}]}, {"title": "Baseline EC < 300 Cells/UL (N= 64, 63, 61)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.84", "spread": "0.14"}, {"groupId": "OG001", "value": "1.05", "spread": "0.13"}, {"groupId": "OG002", "value": "1.15", "spread": "0.15"}]}]}, {"title": "Baseline FEV1 Reversibility >= 12% (n= 39, 29, 32)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.75", "spread": "0.17"}, {"groupId": "OG001", "value": "1.14", "spread": "0.16"}, {"groupId": "OG002", "value": "0.95", "spread": "0.22"}]}]}, {"title": "Baseline FEV1 Reversibility < 12% (n= 66, 76, 67)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.94", "spread": "0.13"}, {"groupId": "OG001", "value": "1.04", "spread": "0.13"}, {"groupId": "OG002", "value": "1.04", "spread": "0.14"}]}]}, {"title": "2 Asthma Exacerbations (n=73, 68, 68)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.88", "spread": "0.13"}, {"groupId": "OG001", "value": "1.09", "spread": "0.14"}, {"groupId": "OG002", "value": "1.14", "spread": "0.15"}]}]}, {"title": ">2 Asthma Exacerbations (n= 34, 41, 33)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.78", "spread": "0.16"}, {"groupId": "OG001", "value": "0.96", "spread": "0.14"}, {"groupId": "OG002", "value": "0.73", "spread": "0.20"}]}]}, {"title": "With Chronic OCS Use (n= 17, 16, 16)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.53", "spread": "0.19"}, {"groupId": "OG001", "value": "0.87", "spread": "0.29"}, {"groupId": "OG002", "value": "0.26", "spread": "0.26"}]}]}, {"title": "Without Chronic OCS Use (n= 90, 93, 85)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.91", "spread": "0.11"}, {"groupId": "OG001", "value": "1.07", "spread": "0.11"}, {"groupId": "OG002", "value": "1.14", "spread": "0.13"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline serum periostin \\>= median", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.211", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "0.23", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.13", "ciUpperLimit": "0.60"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline serum periostin \\>= median", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.397", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "0.16", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.21", "ciUpperLimit": "0.53"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline serum periostin \\< median", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.315", "statisticalMethod": "Repeated Measure Model", "paramType": "Difference of LS-mean", "paramValue": "0.19", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.18", "ciUpperLimit": "0.56"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline serum periostin \\< median", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.166", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "0.26", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.11", "ciUpperLimit": "0.63"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline serum periostin \\>= 25th percentile", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.262", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "0.17", "ciPctValue": "95", "ciLowerLimit": "-0.13", "ciUpperLimit": "0.47"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline serum periostin \\>= 25th percentile", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.379", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "0.14", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.17", "ciUpperLimit": "0.44"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline serum periostin \\< 25th percentile", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.387", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "0.25", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.32", "ciUpperLimit": "0.81"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline serum periostin \\< 25th percentile", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.303", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "0.29", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.26", "ciUpperLimit": "0.84"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline serum periostin \\>=75th percentile", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.127", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "-0.37", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.84", "ciUpperLimit": "0.11"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline serum periostin \\>=75th percentile", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.775", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "-0.07", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.56", "ciUpperLimit": "0.42"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline serum periostin \\< 75th percentile", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.512", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "-0.10", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.38", "ciUpperLimit": "0.19"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline serum periostin \\< 75th percentile", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.404", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "-0.12", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.40", "ciUpperLimit": "0.16"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Th2 high", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.102", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "0.31", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.06", "ciUpperLimit": "0.69"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Th2 high", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.116", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "0.30", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.08", "ciUpperLimit": "0.68"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Th2 low", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.540", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "-0.11", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.47", "ciUpperLimit": "0.25"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Th2 low", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.674", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "-0.07", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.42", "ciUpperLimit": "0.27"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline peripheral blood eosinophil count \\>=150 cells/\u03bcL", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.295", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "0.17", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.15", "ciUpperLimit": "0.49"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline peripheral blood eosinophil count \\>=150 cells/\u03bcL", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.342", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "0.16", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.17", "ciUpperLimit": "0.49"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline peripheral blood eosinophil count \\< 150 cells/\u03bcL", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.406", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "0.18", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.24", "ciUpperLimit": "0.60"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline peripheral blood eosinophil count \\< 150 cells/\u03bcL", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.069", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "0.38", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.03", "ciUpperLimit": "0.79"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline peripheral blood eosinophil count \\>= 300 cells/\u03bcL", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.371", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "0.19", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.23", "ciUpperLimit": "0.62"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline peripheral blood eosinophil count \\>= 300 cells/\u03bcL", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.766", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "0.07", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.37", "ciUpperLimit": "0.51"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline peripheral blood eosinophil count \\< 300 cells/\u03bcL", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.147", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "0.24", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.09", "ciUpperLimit": "0.57"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline peripheral blood eosinophil count \\< 300 cells/\u03bcL", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.031", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "0.35", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.03", "ciUpperLimit": "0.68"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline FEV1 reversibility \\>= 12%", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.020", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "0.59", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.10", "ciUpperLimit": "1.09"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline FEV1 reversibility \\>= 12%", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.226", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "0.29", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.18", "ciUpperLimit": "0.77"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline FEV1 reversibility \\< 12%", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.964", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "0.01", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.31", "ciUpperLimit": "0.33"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Baseline FEV1 reversibility \\< 12%", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.533", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "0.10", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.22", "ciUpperLimit": "0.42"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "2 asthma exacerbations in the past year", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.292", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "0.17", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.15", "ciUpperLimit": "0.50"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "2 asthma exacerbations in the past year", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.097", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "0.27", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.05", "ciUpperLimit": "0.59"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "\\> 2 but \\< 6 asthma exacerbations in the past year", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.260", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "0.24", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.18", "ciUpperLimit": "0.67"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "\\> 2 but \\< 6 asthma exacerbations in the past year", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.648", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "0.10", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.33", "ciUpperLimit": "0.53"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Chronic OCS use", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.398", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "0.28", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.37", "ciUpperLimit": "0.93"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Chronic OCS use", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.327", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "-0.32", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.95", "ciUpperLimit": "0.32"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Without chronic OCS use", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.105", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "0.23", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.05", "ciUpperLimit": "0.52"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Without chronic OCS use", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.030", "statisticalMethod": "Repeated measure model", "paramType": "Difference of LS-mean", "paramValue": "0.31", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.03", "ciUpperLimit": "0.60"}]}, {"type": "SECONDARY", "title": "Annual Asthma Exacerbation Rate (AER) by Atopic Asthma Status", "description": "Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. AER was evaluated by subgroup Atopic and Non-atopic asthma status. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "populationDescription": "The ITT population included all participants who were randomized into the study. Here \"n\" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "AER events/person-year", "timeFrame": "Week 1 up to Week 53", "groups": [{"id": "OG000", "title": "Placebo Total", "description": "Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}, {"id": "OG001", "title": "Tralokinumab 300 mg, Q2W - Cohort 1", "description": "Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks."}, {"id": "OG002", "title": "Tralokinumab 300 mg, Q2/4W - Cohort 2", "description": "Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "151"}]}], "classes": [{"title": "Atopic asthma (n=96,105,92)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.85", "lowerLimit": "0.67", "upperLimit": "1.06"}, {"groupId": "OG001", "value": "0.90", "lowerLimit": "0.73", "upperLimit": "1.11"}, {"groupId": "OG002", "value": "0.85", "lowerLimit": "0.67", "upperLimit": "1.06"}]}]}, {"title": "Non-atopic asthma (n=51,42,55)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.05", "lowerLimit": "0.77", "upperLimit": "1.39"}, {"groupId": "OG001", "value": "0.82", "lowerLimit": "0.56", "upperLimit": "1.15"}, {"groupId": "OG002", "value": "1.10", "lowerLimit": "0.82", "upperLimit": "1.44"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Atopic asthma", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.803", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "0.95", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.62", "ciUpperLimit": "1.44", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Atopic asthma", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.457", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "0.83", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.52", "ciUpperLimit": "1.35", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Non-atopic asthma", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.250", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "0.71", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.40", "ciUpperLimit": "1.27", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Non-atopic asthma", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.794", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "1.07", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.66", "ciUpperLimit": "1.74", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}]}, {"type": "SECONDARY", "title": "Annual Asthma Exacerbation Rate (AER) by Chronic OCS Use", "description": "Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. AER evaluated by subgroup chronic OCS use. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "populationDescription": "The ITT population included all participants who were randomized into the study. Here \"n\" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "AER events/person-year", "timeFrame": "Week 1 up to Week 53", "groups": [{"id": "OG000", "title": "Placebo Total", "description": "Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}, {"id": "OG001", "title": "Tralokinumab 300 mg, Q2W - Cohort 1", "description": "Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks."}, {"id": "OG002", "title": "Tralokinumab 300 mg, Q2/4W - Cohort 2", "description": "Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "151"}]}], "classes": [{"title": "With chronic OCS use (n=27,26,24)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.37", "lowerLimit": "0.93", "upperLimit": "1.94"}, {"groupId": "OG001", "value": "2.04", "lowerLimit": "1.51", "upperLimit": "2.69"}, {"groupId": "OG002", "value": "2.2", "lowerLimit": "1.62", "upperLimit": "2.91"}]}]}, {"title": "Without chronic OCS use (124,124,127)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.81", "lowerLimit": "0.66", "upperLimit": "1.00"}, {"groupId": "OG001", "value": "0.68", "lowerLimit": "0.54", "upperLimit": "0.84"}, {"groupId": "OG002", "value": "0.74", "lowerLimit": "0.59", "upperLimit": "0.91"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "With chronic OCS use", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.614", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "1.20", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.59", "ciUpperLimit": "2.46", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}, {"groupIds": ["OG000", "OG002"], "groupDescription": "With chronic OCS use", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.506", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "1.29", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.61", "ciUpperLimit": "2.74", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Without chronic OCS use", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.243", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "0.79", "ciPctValue": "95", "ciLowerLimit": "0.53", "ciUpperLimit": "1.18", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Without chronic OCS use", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.531", "statisticalMethod": "Poisson regression", "paramType": "Rate Ratio", "paramValue": "0.87", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.57", "ciUpperLimit": "1.34", "estimateComment": "The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs \\>2 but =\\<6), atopic asthma status, chronic OCS use and geographical region as the covariates."}]}, {"type": "SECONDARY", "title": "Change From Baseline in Percentage of Nighttime Awakening at Week 53", "description": "Scores for nighttime awakenings were generated based on the single item (question 5) that had a dichotomous response option (YES/NO). Nighttime awakenings were averaged weekly for participants with at least 4 non-missing records each week. The baseline score was calculated with data from Day -7 to Day -1. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "populationDescription": "The ITT population included all participants who were randomized into the study. Here \"n\" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage change", "timeFrame": "Day -7 - Day -1 (Baseline) and Day 365 - Day 371 (Week 53)", "groups": [{"id": "OG000", "title": "Placebo Total", "description": "Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}, {"id": "OG001", "title": "Tralokinumab 300 mg, Q2W - Cohort 1", "description": "Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks."}, {"id": "OG002", "title": "Tralokinumab 300 mg, Q2/4W - Cohort 2", "description": "Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "151"}]}], "classes": [{"title": "Day -7 - Day -1 (Baseline) (n=151,147,145)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.44", "spread": "0.42"}, {"groupId": "OG001", "value": "0.42", "spread": "0.43"}, {"groupId": "OG002", "value": "0.43", "spread": "0.43"}]}]}, {"title": "Change at Day 365 - Day 371 (n=113,108,108)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.22", "spread": "0.43"}, {"groupId": "OG001", "value": "-0.18", "spread": "0.37"}, {"groupId": "OG002", "value": "-0.23", "spread": "0.45"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Overall Activity Limitations at Week 53", "description": "There were 3 activity limitation questions in the ASMA diary. All activity questions were scored from 0 to 4 and averaged, where the higher score indicated greater limitation. Activity limitation scores were averaged weekly for participants with at least 4 non-missing records each week. The baseline score was calculated from Day -7 to Day -1. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "populationDescription": "The ITT population included all participants who were randomized into the study. Here \"n\" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Day -7 - Day -1 (Baseline) and Day 365 - Day 371 (Week 53)", "groups": [{"id": "OG000", "title": "Placebo Total", "description": "Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}, {"id": "OG001", "title": "Tralokinumab 300 mg, Q2W - Cohort 1", "description": "Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks."}, {"id": "OG002", "title": "Tralokinumab 300 mg, Q2/4W - Cohort 2", "description": "Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "151"}]}], "classes": [{"title": "Day -7 - Day -1 (Baseline) (n=151,147,145)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.71", "spread": "0.86"}, {"groupId": "OG001", "value": "1.52", "spread": "0.90"}, {"groupId": "OG002", "value": "1.63", "spread": "0.85"}]}]}, {"title": "Change at Day 365 - Day 371 (n=113,108,108)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.45", "spread": "0.81"}, {"groupId": "OG001", "value": "-0.38", "spread": "0.84"}, {"groupId": "OG002", "value": "-0.48", "spread": "0.87"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 53", "description": "Pre- and post-bronchodilator FEV1 at clinic visits (morning) were measured. FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms. Baseline for FEV1 was measured in liters.", "populationDescription": "The ITT population included all participants who were randomized into the study. Here \"n\" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage change in liters", "timeFrame": "Baseline and Week 53", "groups": [{"id": "OG000", "title": "Placebo Total", "description": "Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}, {"id": "OG001", "title": "Tralokinumab 300 mg, Q2W - Cohort 1", "description": "Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks."}, {"id": "OG002", "title": "Tralokinumab 300 mg, Q2/4W - Cohort 2", "description": "Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "151"}]}], "classes": [{"title": "Pre-bronchodilator(BD): Baseline (n=147,146,146)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.926", "spread": "0.050"}, {"groupId": "OG001", "value": "1.922", "spread": "0.056"}, {"groupId": "OG002", "value": "1.934", "spread": "0.059"}]}]}, {"title": "Post-BD: Baseline (n=147,141,146)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.153", "spread": "0.053"}, {"groupId": "OG001", "value": "2.094", "spread": "0.061"}, {"groupId": "OG002", "value": "2.110", "spread": "0.061"}]}]}, {"title": "Pre-BD:Change from baseline to W53 (n=125,130,122)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.50", "spread": "1.99"}, {"groupId": "OG001", "value": "9.11", "spread": "2.13"}, {"groupId": "OG002", "value": "2.94", "spread": "1.54"}]}]}, {"title": "Post-BD:Change from baseline to W53(n=125,126,120)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.65", "spread": "1.39"}, {"groupId": "OG001", "value": "5.98", "spread": "1.85"}, {"groupId": "OG002", "value": "0.18", "spread": "1.25"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Forced Expiratory Volume in 6 Second (FEV6) at Week 53", "description": "Pre- and post-bronchodilator FEV6 at clinic visits (morning) were measured. FEV6 was the maximal volume of air exhaled in the six second of a forced expiration from a position of full inspiration. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms. Baseline for FEV6 was measured in liters.", "populationDescription": "The ITT population included all participants who were randomized into the study. Here \"n\" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage change in liters", "timeFrame": "Baseline and Week 53", "groups": [{"id": "OG000", "title": "Placebo Total", "description": "Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}, {"id": "OG001", "title": "Tralokinumab 300 mg, Q2W - Cohort 1", "description": "Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks."}, {"id": "OG002", "title": "Tralokinumab 300 mg, Q2/4W - Cohort 2", "description": "Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "151"}]}], "classes": [{"title": "Pre-bronchodilator(BD): Baseline (n=147,146,146)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.830", "spread": "0.064"}, {"groupId": "OG001", "value": "2.809", "spread": "0.072"}, {"groupId": "OG002", "value": "2.827", "spread": "0.074"}]}]}, {"title": "Post-BD: Baseline (n=147,141,146)", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.055", "spread": "0.067"}, {"groupId": "OG001", "value": "2.981", "spread": "0.075"}, {"groupId": "OG002", "value": "2.980", "spread": "0.076"}]}]}, {"title": "Pre-BD:Change from baseline to W53 (n=125,130,122)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.06", "spread": "1.29"}, {"groupId": "OG001", "value": "5.75", "spread": "1.53"}, {"groupId": "OG002", "value": "1.10", "spread": "1.18"}]}]}, {"title": "Post-BD:Change from baseline to W53(n=125,126,120)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.16", "spread": "1.04"}, {"groupId": "OG001", "value": "3.27", "spread": "1.36"}, {"groupId": "OG002", "value": "-0.11", "spread": "1.01"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Forced Vital Capacity (FVC) at Week 53", "description": "Pre- and post-bronchodilator FVC at clinic visits (morning) were measured. FVC was the volume of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms. Baseline for FVC was measured in liters.", "populationDescription": "The ITT population included all participants who were randomized into the study. Here \"n\" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage change in liters", "timeFrame": "Baseline and Week 53", "groups": [{"id": "OG000", "title": "Placebo Total", "description": "Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}, {"id": "OG001", "title": "Tralokinumab 300 mg, Q2W - Cohort 1", "description": "Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks."}, {"id": "OG002", "title": "Tralokinumab 300 mg, Q2/4W - Cohort 2", "description": "Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "151"}]}], "classes": [{"title": "Pre-bronchodilator(BD): Baseline (n=147,146,146)", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.003", "spread": "0.069"}, {"groupId": "OG001", "value": "2.955", "spread": "0.075"}, {"groupId": "OG002", "value": "2.993", "spread": "0.079"}]}]}, {"title": "Post-BD: Baseline (n=147,141,146)", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.225", "spread": "0.072"}, {"groupId": "OG001", "value": "3.133", "spread": "0.078"}, {"groupId": "OG002", "value": "3.125", "spread": "0.080"}]}]}, {"title": "Pre-BD:Change from baseline to W53 (n=125,130,122)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.87", "spread": "1.31"}, {"groupId": "OG001", "value": "5.43", "spread": "1.60"}, {"groupId": "OG002", "value": "0.46", "spread": "1.17"}]}]}, {"title": "Post-BD:Change from baseline to W53(n=125,126,120)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.51", "spread": "1.01"}, {"groupId": "OG001", "value": "2.56", "spread": "1.27"}, {"groupId": "OG002", "value": "-0.26", "spread": "1.03"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Inspiratory Capacity (IC) at Week 53", "description": "Pre- and post-bronchodilator IC at clinic visits (morning) were measured. IC was measured by spirometry. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms. Baseline for IC was measured in liters.", "populationDescription": "The ITT population included all participants who were randomized into the study. Here \"n\" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage change in liters", "timeFrame": "Baseline and Week 53", "groups": [{"id": "OG000", "title": "Placebo Total", "description": "Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}, {"id": "OG001", "title": "Tralokinumab 300 mg, Q2W - Cohort 1", "description": "Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks."}, {"id": "OG002", "title": "Tralokinumab 300 mg, Q2/4W - Cohort 2", "description": "Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "151"}]}], "classes": [{"title": "Pre-bronchodilator(BD): Baseline (n=140,138,143)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.022", "spread": "0.001"}, {"groupId": "OG001", "value": "0.023", "spread": "0.001"}, {"groupId": "OG002", "value": "0.023", "spread": "0.001"}]}]}, {"title": "Post-BD: Baseline (n=140,133,135)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.024", "spread": "0.001"}, {"groupId": "OG001", "value": "0.024", "spread": "0.001"}, {"groupId": "OG002", "value": "0.024", "spread": "0.001"}]}]}, {"title": "Pre-BD:Change from baseline to W53 (n=108,109,103)", "categories": [{"measurements": [{"groupId": "OG000", "value": "8.56", "spread": "3.42"}, {"groupId": "OG001", "value": "0.15", "spread": "2.21"}, {"groupId": "OG002", "value": "11.38", "spread": "3.71"}]}]}, {"title": "Post-BD:Change from baseline to W53(n=108,109,104)", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.64", "spread": "3.17"}, {"groupId": "OG001", "value": "8.33", "spread": "3.14"}, {"groupId": "OG002", "value": "3.17", "spread": "2.91"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 53 at Home", "description": "Pre- and post-bronchodilator FEV1 at home (morning and evening) were measured. FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "populationDescription": "The ITT population included all participants who were randomized into the study. Here \"n\" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage change", "timeFrame": "Day 1 - Day 7 (Baseline) and Day 365 - Day 371 (Week 53)", "groups": [{"id": "OG000", "title": "Placebo Total", "description": "Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}, {"id": "OG001", "title": "Tralokinumab 300 mg, Q2W - Cohort 1", "description": "Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks."}, {"id": "OG002", "title": "Tralokinumab 300 mg, Q2/4W - Cohort 2", "description": "Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "151"}]}], "classes": [{"title": "Change at Day 365-371: Morning (n=123,119,113)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.96", "spread": "3.27"}, {"groupId": "OG001", "value": "1.67", "spread": "2.83"}, {"groupId": "OG002", "value": "1.70", "spread": "5.41"}]}]}, {"title": "Change at Day 365-371: Evening (n=119,116,111)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.83", "spread": "3.01"}, {"groupId": "OG001", "value": "-2.69", "spread": "3.17"}, {"groupId": "OG002", "value": "-5.78", "spread": "3.63"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Peak Expiratory Flow (PEF) at Week 53 at Home", "description": "The PEF is a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for PEF was performed at home (morning and evening) while sitting or standing prior to using any medication (if needed) for asthma. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.", "populationDescription": "The ITT population included all participants who were randomized into the study. Here \"n\" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage change", "timeFrame": "Day 1 - Day 7 (Baseline) and Day 365 - Day 371 (Week 53)", "groups": [{"id": "OG000", "title": "Placebo Total", "description": "Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}, {"id": "OG001", "title": "Tralokinumab 300 mg, Q2W - Cohort 1", "description": "Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks."}, {"id": "OG002", "title": "Tralokinumab 300 mg, Q2/4W - Cohort 2", "description": "Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "151"}]}], "classes": [{"title": "Change at Day 365-371: Morning (n=123,119,113)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-6.89", "spread": "3.09"}, {"groupId": "OG001", "value": "-0.64", "spread": "3.26"}, {"groupId": "OG002", "value": "-2.80", "spread": "5.41"}]}]}, {"title": "Change at Day 365-371: Evening (n=129,116,111)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.95", "spread": "2.99"}, {"groupId": "OG001", "value": "-6.62", "spread": "3.13"}, {"groupId": "OG002", "value": "-11.45", "spread": "3.33"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "1", "timeFrame": "Baseline up to Week 75", "description": "The safety population included all subjects who received any investigational product and had safety data available.", "eventGroups": [{"id": "EG000", "title": "Placebo Total", "description": "Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.", "seriousNumAffected": 21, "seriousNumAtRisk": 151, "otherNumAffected": 128, "otherNumAtRisk": 151}, {"id": "EG001", "title": "Tralokinumab 300 mg Q2W", "description": "Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.", "seriousNumAffected": 18, "seriousNumAtRisk": 150, "otherNumAffected": 133, "otherNumAtRisk": 150}, {"id": "EG002", "title": "Tralokinumab 300 mg Q2/4W", "description": "Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.", "seriousNumAffected": 25, "seriousNumAtRisk": 151, "otherNumAffected": 128, "otherNumAtRisk": 151}], "seriousEvents": [{"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 3, "numAffected": 2, "numAtRisk": 151}]}, {"term": "Coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}]}, {"term": "Myocarditis", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}]}, {"term": "Sick sinus syndrome", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}]}, {"term": "Colitis ulcerative", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}]}, {"term": "Diabetic gastropathy", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}]}, {"term": "Diverticulum", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}]}, {"term": "Femoral hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}]}, {"term": "Gastric disorder", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}]}, {"term": "Hiatus hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}]}, {"term": "Inguinal hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}]}, {"term": "Large intestine perforation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}]}, {"term": "Abdominal abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}]}, {"term": "Abdominal infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}]}, {"term": "Amoebiasis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}]}, {"term": "Beta haemolytic streptococcal infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}]}, {"term": "Bronchitis bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}]}, {"term": "Diverticulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}]}, {"term": "Pharyngotonsillitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 151}]}, {"term": "Pneumonia pneumococcal", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}]}, {"term": "Septic shock", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}]}, {"term": "Accidental poisoning", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}]}, {"term": "Ankle fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}]}, {"term": "Clavicle fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}]}, {"term": "Concussion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}]}, {"term": "Excoriation", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}]}, {"term": "Head injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}]}, {"term": "Laceration", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}]}, {"term": "Ligament sprain", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}]}, {"term": "Lumbar vertebral fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}]}, {"term": "Road traffic accident", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 151}]}, {"term": "Testicular injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}]}, {"term": "Tibia fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 151}]}, {"term": "Wrist fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}]}, {"term": "Dehydration", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}]}, {"term": "Diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}]}, {"term": "Intervertebral disc protrusion", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}]}, {"term": "Myalgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}]}, {"term": "Rheumatoid arthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}]}, {"term": "Basal cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}]}, {"term": "Squamous cell carcinoma of the cervix", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}]}, {"term": "Neuropathy peripheral", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}]}, {"term": "Renal failure acute", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}]}, {"term": "Dysfunctional uterine bleeding", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}]}, {"term": "Menometrorrhagia", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}]}, {"term": "Allergic sinusitis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 9, "numAffected": 6, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 13, "numAffected": 9, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 13, "numAffected": 10, "numAtRisk": 151}]}, {"term": "Pulmonary embolism", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}]}, {"term": "Angioedema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}]}, {"term": "Peripheral artery thrombosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}]}], "otherEvents": [{"term": "Anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}]}, {"term": "Conjunctivitis", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 151}]}, {"term": "Conjunctivitis allergic", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 151}]}, {"term": "Eye pruritus", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 151}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 12, "numAffected": 9, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 3, "numAffected": 1, "numAtRisk": 151}]}, {"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 4, "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 151}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 4, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 151}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 19, "numAffected": 12, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 7, "numAffected": 5, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 10, "numAffected": 7, "numAtRisk": 151}]}, {"term": "Dyspepsia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}]}, {"term": "Gastritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 4, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 151}]}, {"term": "Gastrooesophageal reflux disease", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 6, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 151}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 15, "numAffected": 7, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 7, "numAffected": 2, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 4, "numAffected": 3, "numAtRisk": 151}]}, {"term": "Toothache", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 20, "numAffected": 8, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 6, "numAffected": 4, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 2, "numAffected": 1, "numAtRisk": 151}]}, {"term": "Administration site rash", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 13, "numAffected": 3, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 151}]}, {"term": "Asthenia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 6, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 2, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 4, "numAffected": 2, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 4, "numAffected": 3, "numAtRisk": 151}]}, {"term": "Injection site erythema", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 58, "numAffected": 12, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 15, "numAffected": 7, "numAtRisk": 151}]}, {"term": "Injection site haemorrhage", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 3, "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 3, "numAffected": 2, "numAtRisk": 151}]}, {"term": "Injection site pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 90, "numAffected": 15, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 23, "numAffected": 7, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 61, "numAffected": 11, "numAtRisk": 151}]}, {"term": "Injection site pruritus", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 12, "numAffected": 8, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 2, "numAffected": 1, "numAtRisk": 151}]}, {"term": "Injection site reaction", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 32, "numAffected": 7, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 4, "numAffected": 2, "numAtRisk": 151}]}, {"term": "Injection site swelling", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 2, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 151}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 10, "numAffected": 6, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 3, "numAffected": 2, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 6, "numAffected": 4, "numAtRisk": 151}]}, {"term": "Acute sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 5, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 4, "numAffected": 3, "numAtRisk": 151}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 48, "numAffected": 22, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 44, "numAffected": 27, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 27, "numAffected": 20, "numAtRisk": 151}]}, {"term": "Cystitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 9, "numAffected": 9, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 9, "numAffected": 7, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 6, "numAffected": 6, "numAtRisk": 151}]}, {"term": "Herpes zoster", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 15, "numAffected": 13, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 13, "numAffected": 11, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 15, "numAffected": 14, "numAtRisk": 151}]}, {"term": "Lower respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 4, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 83, "numAffected": 40, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 57, "numAffected": 35, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 62, "numAffected": 26, "numAtRisk": 151}]}, {"term": "Oral candidiasis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 3, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 6, "numAffected": 6, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 151}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 15, "numAffected": 9, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 9, "numAffected": 6, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 18, "numAffected": 11, "numAtRisk": 151}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 151}]}, {"term": "Respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 10, "numAffected": 6, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}]}, {"term": "Rhinitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 10, "numAffected": 9, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 9, "numAffected": 8, "numAtRisk": 151}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 15, "numAffected": 10, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 10, "numAffected": 8, "numAtRisk": 151}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 28, "numAffected": 18, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 36, "numAffected": 20, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 25, "numAffected": 20, "numAtRisk": 151}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 19, "numAffected": 9, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 16, "numAffected": 11, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 8, "numAffected": 8, "numAtRisk": 151}]}, {"term": "Viral infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 5, "numAffected": 4, "numAtRisk": 151}]}, {"term": "Contusion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 2, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 6, "numAffected": 3, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 4, "numAffected": 4, "numAtRisk": 151}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 3, "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 151}]}, {"term": "Foot fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 151}]}, {"term": "Ligament sprain", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 6, "numAffected": 5, "numAtRisk": 151}]}, {"term": "Rib fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 151}]}, {"term": "Hyperglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 151}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 6, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 15, "numAffected": 10, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 11, "numAffected": 9, "numAtRisk": 151}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 11, "numAffected": 9, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 11, "numAffected": 8, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 12, "numAffected": 10, "numAtRisk": 151}]}, {"term": "Muscle spasms", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 8, "numAffected": 5, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 6, "numAffected": 6, "numAtRisk": 151}]}, {"term": "Musculoskeletal chest pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}]}, {"term": "Musculoskeletal pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 151}]}, {"term": "Myalgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 7, "numAffected": 6, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 11, "numAffected": 8, "numAtRisk": 151}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 5, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 9, "numAffected": 8, "numAtRisk": 151}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 17, "numAffected": 9, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 3, "numAffected": 2, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 151}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 36, "numAffected": 17, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 38, "numAffected": 17, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 22, "numAffected": 17, "numAtRisk": 151}]}, {"term": "Migraine", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 14, "numAffected": 3, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}]}, {"term": "Depression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 6, "numAffected": 6, "numAtRisk": 151}]}, {"term": "Insomnia", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 175, "numAffected": 73, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 192, "numAffected": 68, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 188, "numAffected": 58, "numAtRisk": 151}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 9, "numAffected": 6, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 7, "numAffected": 7, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 11, "numAffected": 8, "numAtRisk": 151}]}, {"term": "Dysphonia", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 5, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 4, "numAffected": 3, "numAtRisk": 151}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 16, "numAffected": 7, "numAtRisk": 151}]}, {"term": "Nasal congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 151}]}, {"term": "Oropharyngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 7, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 7, "numAffected": 6, "numAtRisk": 151}]}, {"term": "Productive cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 5, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 2, "numAffected": 1, "numAtRisk": 151}]}, {"term": "Rhinitis allergic", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 3, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 13, "numAffected": 11, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 151}]}, {"term": "Rhinorrhoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 5, "numAffected": 4, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 151}]}, {"term": "Upper respiratory tract inflammation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 2, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 5, "numAffected": 3, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 9, "numAffected": 4, "numAtRisk": 151}]}, {"term": "Wheezing", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 2, "numAffected": 1, "numAtRisk": 151}]}, {"term": "Dermatitis", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 2, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 151}]}, {"term": "Dermatitis contact", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 151}]}, {"term": "Pruritus", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 7, "numAffected": 7, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 151}]}, {"term": "Pruritus generalised", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 4, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 2, "numAffected": 1, "numAtRisk": 151}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 2, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 151}]}, {"term": "Urticaria", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 5, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 151}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 6, "numAtRisk": 151}, {"groupId": "EG001", "numEvents": 8, "numAffected": 8, "numAtRisk": 150}, {"groupId": "EG002", "numEvents": 10, "numAffected": 9, "numAtRisk": 151}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication."}, "pointOfContact": {"title": "Meena Jain, MB BChir, Director, Clinical Development,", "organization": "MedImmune, LLC", "email": "JainM@medimmune.com", "phone": "301-398-0000"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Brazil"]}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000000911", "term": "Antibodies, Monoclonal"}], "ancestors": [{"id": "D000007155", "term": "Immunologic Factors"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M10184", "name": "Immunoglobulins", "relevance": "LOW"}, {"id": "M4225", "name": "Antibodies", "relevance": "LOW"}, {"id": "M4230", "name": "Antibodies, Monoclonal", "asFound": "Prenatal care", "relevance": "HIGH"}, {"id": "M10201", "name": "Immunologic Factors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}